Intelligent Bio Solutions (INBS) 10-K 18 Sep 24 2024 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Jun. 30, 2024	Sep. 16, 2024	Dec. 31, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--06-30
Entity File Number	001-39825
Entity Registrant Name	Intelligent Bio Solutions Inc.
Entity Central Index Key	0001725430
Entity Tax Identification Number	82-1512711
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	Intelligent Bio Solutions Inc.,
Entity Address, Address Line Two	135 West, 41ST Street,
Entity Address, Address Line Three	5th Floor,
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10036
City Area Code	(646)
Local Phone Number	828-8258
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	INBS
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 5,986,356
Entity Common Stock, Shares Outstanding		4,249,782
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Auditor Firm ID	1195
Auditor Name	UHY LLP
Auditor Location	Melville, New York

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)		Jun. 30, 2024	Jun. 30, 2023
Current assets
Cash and cash equivalents	[1]	$ 6,304,098	$ 1,537,244
Accounts receivable, net	[1]	429,704	293,861
Inventories, net	[1]	777,537	979,907
Research and development tax incentive receivable	[1]	525,332	498,758
Other current assets	[1]	497,572	552,791
Total current assets	[1]	8,534,243	3,862,561
Property and equipment, net	[1]	565,850	690,175
Operating lease right of use assets	[1]	306,744	546,475
Intangible assets, net	[1]	4,372,026	5,255,401
Total assets	[1]	13,778,863	10,354,612
Current liabilities
Accounts payable and accrued expenses	[1]	1,704,568	2,610,028
Current portion of operating lease liabilities	[1]	274,834	223,447
Current portion of deferred grant income	[1]	2,486,668	2,338,057
Current employee benefit liabilities	[1]	469,381	358,942
Current portion of notes payable	[1]	515,282	353,211
Total current liabilities	[1]	5,450,733	5,883,685
Employee benefit liabilities, less current portion	[1]	63,615	24,902
Operating lease liabilities, less current portion	[1]	81,324	356,165
Notes payable, less current portion	[1]		402,862
Total liabilities	[1]	5,595,672	6,667,614
Commitments and contingencies (Note 16)	[1]
Shareholders’ equity
Common stock, $0.01 par value, 100,000,000 shares authorized, 3,456,000 and 194,200 shares issued and outstanding at June 30, 2024 and 2023, respectively	[1]	34,557	1,942
Treasury stock, at cost, 116 shares as of June 30, 2024 and 2023, respectively	[1]	(1)	(1)
Additional paid-in capital	[1]	60,971,740	46,180,112
Accumulated deficit	[1]	(51,964,332)	(41,807,573)
Accumulated other comprehensive loss	[1]	(712,614)	(575,496)
Total consolidated Intelligent Bio Solutions Inc. equity	[1]	8,329,350	3,798,984
Non-controlling interest	[1]	(146,159)	(111,986)
Total shareholders’ equity	[1]	8,183,191	3,686,998
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	[1]	$ 13,778,863	$ 10,354,612
[1]Common Stock has been retroactively adjusted to reflect the decreased number of shares resulting from the

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2024	Jun. 30, 2023
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	3,456,000	194,200
Common stock, shares outstanding	3,456,000	194,200
Treasury stock shares	116	116

Consolidated Statements of Oper

Consolidated Statements of Operations and Other Comprehensive Income (Loss) - USD ($)		12 Months Ended
		Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Revenue	[1]	$ 3,111,781	$ 1,256,872
Cost of revenue (exclusive of amortization shown separately below)	[1]	(1,686,155)	(930,204)
Gross profit	[1]	1,425,626	326,668
Other income:
Government support income	[1]	424,776	737,628
Operating expenses:
Selling, general and administrative expenses	[1]	(9,258,496)	(8,026,703)
Development and regulatory approval expenses	[1]	(1,673,806)	(507,424)
Depreciation and amortization	[1]	(1,201,274)	(966,732)
Goodwill impairment	[1]		(4,158,670)
Total operating expenses	[1]	(12,133,576)	(13,659,529)
Loss from operations	[1]	(10,283,174)	(12,595,233)
Other income (expense), net:
Interest expense	[1]	(167,140)	(223,534)
Realized foreign exchange loss	[1]	(1,178)	(9,829)
Fair value gain on revaluation of financial instrument	[1]	175,738	2,154,365
Interest income	[1]	84,822	9,676
Total other income, net	[1]	92,242	1,930,678
Net loss	[1],[2]	(10,190,932)	(10,664,555)
Net loss attributable to non-controlling interest	[1]	(34,173)	(32,835)
Net loss attributable to Intelligent Bio Solutions Inc.	[1]	(10,156,759)	(10,631,720)
Other comprehensive income (loss), net of tax:
Foreign currency translation gain/ (loss)	[1],[2]	(137,118)	212,639
Total other comprehensive income (loss)	[1]	(137,118)	212,639
Comprehensive loss	[1]	(10,328,050)	(10,451,916)
Comprehensive loss attributable to non-controlling interest	[1]	(34,173)	(32,835)
Comprehensive loss attributable to Intelligent Bio Solutions Inc.	[1]	$ (10,293,877)	$ (10,419,081)
Net loss per share basic	[1]	$ (6.38)	$ (127)
Net loss per share diluted	[1]	$ (6.38)	$ (127)
Weighted average shares outstanding, basic	[1]	1,592,746	83,717
Weighted average shares outstanding, diluted	[1]	1,592,746	83,717
[1]Common Stock and per share amounts have been retroactively adjusted to reflect the decreased number of shares resulting from the[2]Common Stock has been retroactively adjusted to reflect the decreased number of shares resulting from the

Consolidated Statements of Op_2

Consolidated Statements of Operations and Other Comprehensive Income (Loss) (Parenthetical)	Jan. 26, 2024	Feb. 09, 2023
Income Statement [Abstract]
Stockholders' Equity, Reverse Stock Split	1-for-12	1-for-20

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - USD ($)		Preferred Stock [Member] Convertible Preferred Stock [Member]		Common Stock [Member]		Treasury Stock, Common [Member]		Additional Paid-in Capital [Member]		Retained Earnings [Member]		AOCI Attributable to Parent [Member]		Noncontrolling Interest [Member]		Total
Balance at Jun. 30, 2022	[1]			$ 620				$ 38,588,290		$ (31,175,853)		$ (788,135)		$ (79,151)		$ 6,545,771
Balance, shares at Jun. 30, 2022	[1]			62,042
Reverse stock split rounding adjustment	[1]			$ 9				(9)
Reverse stock split rounding adjustment, shares	[1]															938
Issuance of Series C preferred stock and common stock for acquisition, net of issuance costs	[1]	$ 23,630		$ 124				4,700,516								$ 4,724,270
Issuance of Series C preferred stock and common stock for acquisition, net of issuance costs, shares	[1]	2,363,003		12,347
Issuance of Series D preferred stock, net of issuance costs	[1]	$ 1,765						160,695								162,460
Issuance of Series D preferred stock, net of issuance costs, shares	[1]	176,462
Stock awards issued to employees	[1]			$ 21				259,979								260,000
Stock awards issued to employees, shares	[1]			2,084
Payment of tax withholding for employee stock awards	[1]					$ (1)		(14,406)								(14,407)
Payment of tax withholding for employee stock awards, shares	[1]					(116)
Issuance of common stock, Series E Preferred Stock and warrants, net of issuance costs	[1]			$ 546				2,093,121								2,093,667
Issuance of common stock, Series E preferred stock and warrants, net of issuance costs, shares	[1]			54,583
Issuance of common stock upon cashless exercise Series F warrants	[1]			$ 161				(161)
Issuance of common stock upon cashless exercise Series F warrants, shares	[1]			16,099
Conversion of convertible notes payable into Series C preferred stock	[1]	$ 11,493						355,660								367,153
Conversion of convertible notes payable into Series C preferred stock, shares	[1]	1,149,274
Conversion of convertible preferred shares into common stock	[1]	$ (36,888)		$ 461				36,427
Conversion of convertible preferred shares into common stock, shares	[1]	(3,688,739)		46,107
Foreign currency translation loss	[1]											212,639				212,639	[2]
Net loss	[1]									(10,631,720)				(32,835)		(10,664,555)	[2]
Balance at Jun. 30, 2023			[1]	$ 1,942	[1]	$ (1)	[1]	46,180,112	[1]	(41,807,573)	[1]	(575,496)	[1]	(111,986)	[1]	3,686,998	[3]
Balance, shares at Jun. 30, 2023	[1]			194,200		(116)
Reverse stock split rounding adjustment	[1]			$ 475				(475)
Reverse stock split rounding adjustment, shares	[1]			47,501
Stock awards issued to employees	[1]			$ 58				13,617								13,675
Stock awards issued to employees, shares	[1]			5,762
Issuance of common stock, Series E Preferred Stock and warrants, net of issuance costs	[1]	$ 57,287		$ 1,860				3,727,017								3,786,164
Issuance of common stock, Series E preferred stock and warrants, net of issuance costs, shares	[1]	5,728,723		186,018
Issuance of common stock upon cashless exercise Series F warrants	[1]			$ 6,551				(6,122)								429
Issuance of common stock upon cashless exercise Series F warrants, shares	[1]			655,086
Conversion of convertible preferred shares into common stock	[1]	$ (57,287)		$ 4,774				52,513
Conversion of convertible preferred shares into common stock, shares	[1]	(5,728,723)		477,394
Foreign currency translation loss	[1]											(137,118)				(137,118)	[2]
Net loss	[1]									(10,156,759)				(34,173)		(10,190,932)	[2]
Conversion of holdback Series C Preferred Stock into common stock	[1]			$ 62				32,700								32,762
Conversion of holdback Series C Preferred Stock into common stock, shares	[1]			6,248
Issuance of common stock upon cash exercise of Series E warrants	[1]			$ 6,291				1,645,207								1,651,498
Issuance of common stock, Series E preferred stock and warrants, net of issuance costs, shares	[1]			629,409
Issuance of restricted stock to vendors	[1]			$ 479				216,342								216,821
Issuance of restricted stock to vendors, shares	[1]			47,889
Issuance of common stock, Series I, H1 and H2 warrants, net of issuance costs	[1]			$ 6,752				9,110,829								9,117,581
Issuance of common stock, Series I, H1 and H2 warrants, net of issuance costs, shares	[1]			675,183
Issuance of common stock upon exercise of Pre-funded warrants	[1]			$ 5,313												5,313
Issuance of common stock upon exercise of Pre-funded warrants, shares	[1]			531,310
Balance at Jun. 30, 2024			[1]	$ 34,557	[1]	$ (1)	[1]	$ 60,971,740	[1]	$ (51,964,332)	[1]	$ (712,614)	[1]	$ (146,159)	[1]	$ 8,183,191	[3]
Balance, shares at Jun. 30, 2024	[1]			3,456,000		(116)
[1]Common Stock has been retroactively adjusted to reflect the decreased number of shares resulting from the[2]Common Stock and per share amounts have been retroactively adjusted to reflect the decreased number of shares resulting from the[3]Common Stock has been retroactively adjusted to reflect the decreased number of shares resulting from the

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Shareholders' Equity (Parenthetical)	Jan. 26, 2024	Feb. 09, 2023
Statement of Stockholders' Equity [Abstract]
Stockholders' Equity, Reverse Stock Split	1-for-12	1-for-20

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)		12 Months Ended
		Jun. 30, 2024	Jun. 30, 2023
Cash Flows from Operating Activities
Net loss	[1],[2]	$ (10,190,932)	$ (10,664,555)
Adjustment to reconcile net loss to cash used in operating activities:
Depreciation and amortization		974,355	814,481
Amortization on right-of-use assets		238,730	152,251
Non-cash loss on foreign currency translation, net		1,178	9,829
Provision for credit losses		6,772
Provision for inventory obsolescence		69,676	189,670
Goodwill impairment	[2]		4,158,670
Share-based compensation		230,496	260,000
Non-cash refund of R&D expenditure claims			(127,944)
Fair value gain on revaluation of convertible notes			(1,537,565)
Fair value gain on revaluation of holdback Series C Preferred Stock		(175,738)	(616,800)
Non-cash other operating activities		(24,177)	(94,332)
Changes in operating assets and liabilities:
Accounts receivable		(135,843)	(293,861)
Inventories		202,370	(345,390)
Grant receivable/deferred grant income		148,611	1,031,357
Research and development tax incentive receivable		(26,574)	(145,710)
Other current assets		55,219	(118,335)
Accounts and other payables		(632,950)	84,502
Other long-term liabilities		(364,149)	(25,724)
Operating lease liabilities		51,387	(107,922)
Net cash used in operating activities		(9,571,569)	(7,377,378)
Cash flows from Investing Activities
Cash acquired from business acquisition			174,481
Cash payment for business acquisition			(363,500)
Purchase of fixed assets		(5,368)
Amount invested on capital work in progress		(216,058)	(505,123)
Net cash used in investing activities		(221,426)	(694,142)
Cash flows from Financing Activities
Proceeds from issuance of common stock and warrants		3,786,164	2,554,463
Proceeds from exercise of warrants		1,656,811
Proceeds from private placement		9,117,581
Proceeds from issuance of preferred stock			220,578
Payment of equity issuance costs - others			(518,914)
Payment of equity issuance costs relating to acquisition of IFP			(806,397)
Payment of tax withholding for employee stock awards			(14,407)
Net cash provided by financing activities		14,560,556	1,435,323
Effect of foreign exchange rates on cash and cash equivalents		(707)	(64,860)
Net increase in cash and cash equivalents		4,766,854	(6,701,057)
Cash and cash equivalents, beginning of period		1,537,244	8,238,301
Cash and cash equivalents, end of the period		6,304,098	1,537,244
Non-cash investing and financing activities
Shares issued for business acquisition			5,530,667
Note receivable settled for business acquisition			504,938
Deferred consideration payable for business combination			208,500
Recording of right-of-use asset and lease liability			702,566
Conversion of convertible notes payable into preferred stock			367,153
Conversion of preferred stock into common stock		57,287	36,888
Conversion of holdback Series C Preferred Stock into common stock		32,762
Issuance of common stock upon cashless exercise of Series F warrants		$ 6,551
[1]Common Stock has been retroactively adjusted to reflect the decreased number of shares resulting from the[2]Common Stock and per share amounts have been retroactively adjusted to reflect the decreased number of shares resulting from the

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)		12 Months Ended
		Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	[1]	$ (10,156,759)	$ (10,631,720)
[1]Common Stock and per share amounts have been retroactively adjusted to reflect the decreased number of shares resulting from the

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

ORGANIZATION AND DESCRIPTION OF

ORGANIZATION AND DESCRIPTION OF THE BUSINESS	12 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND DESCRIPTION OF THE BUSINESS	NOTE 1. ORGANIZATION AND DESCRIPTION OF THE BUSINESS Business Intelligent Bio Solutions Inc. and its wholly owned Delaware subsidiary, GBS Operations Inc., were each formed on December 5, 2016, under the laws of the state of Delaware. The Company’s Australian subsidiary, Intelligent Bio Solutions (APAC) Pty Ltd, was formed on August 4, 2016, under the laws of New South Wales, Australia and was renamed to Intelligent Bio Solutions (APAC) Pty Ltd on January 6, 2023. On October 4, 2022, INBS acquired Intelligent Fingerprinting Limited (“IFP”), a company registered in England and Wales (the “IFP Acquisition”). The Company’s headquarters are in New York, New York. Intelligent Bio Solutions Inc. is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. The Company operates globally with the objective of providing innovative and accessible solutions that improve the quality of life. Reverse Stock Splits January 2024 Reverse Stock Split On January 26, 2024, the Company filed a certificate of amendment to its amended and restated certificate of incorporation to effect, as of 5:00 p.m. January 26, 2024, a 1-for-12 February 2023 Reverse Stock Split On February 9, 2023, the Company filed a certificate of amendment to its amended and restated certificate of incorporation to effect, as of 5:00 p.m. February 9, 2023, a 1-for-20 The reverse stock splits were implemented for the purpose of regaining compliance with the minimum bid price requirement for continued listing of the Company’s common stock on the Nasdaq Capital Market. Unless otherwise indicated, all authorized, issued, and outstanding stock and per share amounts contained in the accompanying consolidated financial statements have been adjusted to reflect both the 1-for-20 1-for-12

LIQUIDITY AND GOING CONCERN

LIQUIDITY AND GOING CONCERN	12 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
LIQUIDITY AND GOING CONCERN	NOTE 2. LIQUIDITY AND GOING CONCERN On October 4, 2023, the Company raised approximately $ 4.38 3.79 On February 7, 2024, the Company raised approximately $ 1.77 1.58 On March 12, 2024, the Company raised approximately $ 10.10 9.12 The Company incurred a net loss of approximately $ 10.16 million for the year ended June 30, 2024. As of June 30, 2024, the Company had shareholders’ equity of approximately $ 8.18 , working capital of approximately $ 3.08 51.96 The Company anticipates operating losses for the foreseeable future. The Company does not expect to generate positive cash flows from operating activities and may continue to incur operating losses until it sufficiently delivers on its objectives which include completion of the regulatory approval process in the United States of America (USA) and other markets where such approval may be required, expansion of its revenue base into target markets, and the continued development of its products. The ability to achieve these objectives is subject to inherent risks and no assurance can be provided that these objectives will be fully achieved within the next 12 months. The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise a substantial doubt about its ability to continue as going concern within one year after the date of release of these consolidated financial statements. Management believes there is material risk that the Company’s cash and cash equivalents as of June 30, 2024, of approximately $ 6.30 Accordingly, these factors raise substantial doubt about the Company’s ability to continue as a going concern unless it can successfully meet the stated objectives and/or raise additional capital. The Company’s consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities should the Company be unable to continue as a going concern.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of presentation The consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) as of June 30, 2024 and 2023. The consolidated financial statements and notes thereto give retrospective effect to the stock splits for all periods presented. All common stock, options exercisable for common stock, restricted stock units, warrants and per share amounts contained in the consolidated financial statements have been retrospectively adjusted to reflect the stock splits for all periods presented. Principles of consolidation These consolidated financial statements include the accounts of the Company, all wholly owned and majority-owned subsidiaries in which the Company has a controlling voting interest and, when applicable, variable interest entities in which the Company has a controlling financial interest or is the primary beneficiary. Investments in affiliates where the Company does not exert a controlling financial interest are not consolidated. All significant intercompany transactions and balances have been eliminated upon consolidation. Foreign currency translation Assets and liabilities of foreign subsidiaries are translated from local (functional) currency to reporting currency (U.S. dollar) at the spot rate on the consolidated balance sheets date; income and expenses are translated at the average rate of exchange prevailing during the year. Adjustments resulting from translating local currency financial statements into U.S. dollars are reflected in accumulated other comprehensive loss in total shareholders’ equity. The functional currency of INBS is the United States dollar. The settlement of transactions denominated in a currency other than the functional currency resulted in a loss of $ 137,118 212,639 Use of estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Significant estimates made by management in connection with the preparation of the accompanying consolidated financial statements including the fair value measurement of and the useful lives of long-lived assets, inventory valuations, the allocation of transaction price among various performance obligations, and the allowance for credit losses. Actual results could materially differ from those estimates. Risks and Uncertainties The Company’s future results of operations and liquidity could be materially adversely affected by macroeconomic factors contributing to delays in payments from customers and inflationary pressure, uncertain or reduced demand, and the impact of any initiatives or programs that the Company may undertake to address financial and operational challenges faced by its customers. See associated risk factors in Item 1A. Risk Factors in Item 1A Risk Factors in this Annual Report on Form 10-K. Cash and cash equivalents The Company considers all highly liquid investments with a maturity of 90 days or less to be cash equivalents. The carrying values of cash and cash equivalents approximate their fair values due to the short-term nature of these instruments. As of June 30, 2024 and 2023, there were no Concentration of credit risk The Company places its cash and cash equivalents, which may at times be in excess of the Australia Financial Claims Scheme, Financial Services Compensation Scheme or the United States’ Federal Deposit Insurance Corporation insurance limits, with high credit quality financial institutions and attempts to limit the amount of credit exposure with any one institution. The amounts over these insured limits as of June 30, 2024 and 2023 were $ 5,781,130 1,114,687 Fair value measurements The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1 Level 2 Level 3 Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The carrying amounts of cash equivalents, prepaid and other assets, accounts payable and accrued liabilities are representative of their respective fair values because of the short-term nature of those instruments. Inventories, net Inventories are stated at the lower of cost or net realizable value. Cost comprises direct materials and, where applicable, other costs that have been incurred in bringing the inventories to their present location and condition. Net realizable value is the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution. General market conditions, as well as the Company’s research activities, can cause certain of its products to become obsolete. The Company writes down excess and obsolete inventories based upon a regular analysis of inventory on hand compared to historical and projected demand. The determination of projected demand requires the use of estimates and assumptions related to projected sales for each product. These write downs can influence results from operations. Equity offering costs The Company complies with the requirements of Accounting Standards Codification (“ASC”) 340, Other Assets and Deferred Costs Property, Plant and Equipment (“PPE”) & Construction in Progress (“CIP”) In accordance with the ASC 360, Property, Plant, and Equipment ● Other equipment – 3 ● Production equipment – 2 4 ● Leasehold improvements – shorter of asset’s estimated useful life and the remaining term of the lease The assets’ residual values, useful lives and methods of depreciation are reviewed periodically and adjusted prospectively, if appropriate. Equipment is derecognized upon disposal or when no future economic benefits are expected from its use. Any gain or loss arising upon de-recognition of the asset (calculated as the difference between the net disposal proceeds, if any, and the carrying value of the asset) is included in gain or loss on sale of assets in the consolidated statements of operations in the period the asset is derecognized. Leases The Company determines if an arrangement is a lease at its inception. Lease arrangements are comprised primarily of real estate for which the right-of-use (“ROU”) assets and the corresponding lease liabilities are presented separately on the consolidated balance sheet. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The lease term includes options to extend the lease when it is reasonably certain that the option will be exercised. Leases with a term of 12 months or less are not recorded on the consolidated balance sheet. The Company uses its estimated incremental borrowing rate in determining the present value of lease payments considering the term of the lease, which is derived from information available at the lease commencement date, considering publicly available data for instruments with similar characteristics. The Company accounts for the lease and non-lease components as a single lease component. Intangible assets Intangible assets are considered long-lived assets and are recorded at cost, less accumulated amortization and impairment losses, if any. The definite-lived intangible assets are amortized over their estimated useful lives, which do not exceed any contractual periods. Certain of our intangible assets have been assigned an indefinite life as we currently anticipate that these trade names and trademarks will contribute cash flows to the Company indefinitely. Indefinite-lived intangible assets are not amortized but are evaluated at least annually to determine whether the indefinite useful life is appropriate. Amortization is recorded on a straight-line basis over their estimated useful lives. Intangible assets acquired from a foreign operation are translated from the foreign entity’s functional currency to the presentational currency based on the exchange rate at the reporting date. Impairment of long-lived assets Long-lived assets include acquired property and equipment, right of use assets and other intangible assets subject to amortization. The Company evaluates the recoverability of long-lived assets for possible impairment whenever events or changes in circumstances indicate that the related carrying amount may not be recoverable. Such events and changes may include significant changes in performance relative to expected operating results, significant changes in asset use, significant negative industry or economic trends, and changes in the Company’s business strategy. Recoverability is measured by a comparison of the carrying amount of an asset or asset group to the undiscounted future cash flows expected to be generated by the asset or asset group. When required, impairment losses on assets to be held and used are recognized based on the excess of the asset’s carrying amount over the fair value of the asset, while long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. During the fiscal year ended June 30, 2023, the Company recognized an impairment charge of $ 4.2 million in the IFPG segment, which is related to the goodwill associated with the IFP Acquisition. Following the impairment charge the goodwill balance was zero. For the year ended June 30, 2024, the Company did not record any impairment charges on its long-lived assets. Business combinations The results of businesses acquired in a business combination are included in the Company’s consolidated financial statements from the date of the acquisition. The Company uses the acquisition method of accounting and allocates the purchase price to the identifiable assets and liabilities of the relevant acquired business at their acquisition date fair values. Any excess consideration over the fair value of assets acquired and liabilities assumed is recognized as goodwill. The allocation of the purchase price in a business combination requires the Company to perform valuations with significant judgment and estimates, including the selection of valuation methodologies, estimates of future revenue, costs and cash flows, discount rates and selection of comparable companies. The Company engages the assistance of valuation specialists in concluding on fair value measurements in connection with determining fair value of assets acquired and liabilities assumed in a business combination. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company records adjustments to the assets acquired and liabilities assumed with a corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statements of operations. Transaction costs associated with business combinations are expensed as incurred and are included in selling, general and administrative expenses in the consolidated statements of operations. Revenue recognition In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue from its contracts with customers when it satisfies its performance obligations by delivering the promised goods or service deliverables to the customers. A good or service deliverable is transferred to a customer when, or as, the customer obtains control of the good or service deliverable. Financial information presented on a consolidated basis is accompanied by disaggregated information about revenue and other income by product type for the purpose of allocating resources and evaluating financial performance. Currently, the Company has two products offerings. Accordingly, the Company has determined the following reporting segments (refer to Note 4, Segment Information): 1) Commercially available Intelligent Fingerprinting Products (“IFPG” or “IFPG segment”) 2) Development Stage Biosensor Platform Technology (“BPT segment”) Revenue is used to evaluate the performance of the Company’s segments, the progress of major initiatives and the allocation of resources. All of the Company’s revenues is attributable to the IFPG segment during the years ended June 30, 2024 and 2023. Revenue from the IFPG segment relates to the sale of readers, cartridges and other sales which represents accessories and is summarized as follows: SCHEDULE OF REVENUE SALES OF READERS CARTRIDGES AND OTHER SALES WHICH REPRESENTS ACCESSORIES 2024 2023 Year ended June 30, 2024 2023 Sales of goods - cartridges $ 1,549,409 $ 724,304 Sales of goods - readers 938,897 335,863 Other sales 623,475 196,705 Total revenue $ 3,111,781 $ 1,256,872 Other income The other income is mainly comprised of grant income and Research & Development (“R&D”) tax refund. a) Grant income On June 30, 2021, the Company executed a definitive grant agreement with the Australian Government to assist with building a manufacturing facility. The grant has a total value of up to $ 4.7 Accounting for the grant does not fall under ASC 606, Revenue from Contracts with Customers Accounting for Government Grants and Disclosure of Government Assistance Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance The Australian Government grant proceeds, which will be used to reimburse construction costs incurred, meet the definition of grants related to assets as the primary purpose for the payments is to fund the construction of a capital asset. Pursuant to IAS 20, the Company has elected to record the grants received initially as deferred income and deduct the grant proceeds received from the gross costs of the assets or construction in progress (“CIP”) and the deferred grant income liability. A total of $ 543,410 646,116 Under IAS 20, government grants are initially recognized when there is reasonable assurance the conditions of the grant will be met and the grant will be received. As of June 30, 2021, management concluded that there was reasonable assurance the grant conditions will be met and all milestone payments received. The total grant value of $ 4.7 1.65 After initial recognition, under IAS 20, government grants are recognized in earnings on a systematic basis in a manner that mirrors the manner in which the Company recognizes the underlying costs for which the grant is intended to compensate. Pursuant to IS 20, the Company has elected to recognize government grant income separately within other income for operating expenditures. Similarly, for capital expenditures, the carrying amount of assets purchased or constructed out of the grant funds are presented net by deducting the grant proceeds received from the gross costs of the assets or CIP and deferred grant income liability. There was no deferred grant income recognized within other income during the year ended June 30, 2024. A total of $ 127,944 deferred grant income was recognized within other income during the year ended June 30, 2023. b) R&D tax refund The Company measures the R&D grant income and receivable by considering the time spent by employees on eligible R&D activities and R&D costs incurred to external service providers. The R&D tax refund receivable is recognized when it is probable that the amount will be recovered in full through a future claim. A total of $ 424,776 609,684 Development and regulatory approval costs Expenditures relating to R&D are expensed as incurred and recorded in development and regulatory approval in the consolidated statements of operations and other comprehensive loss. R&D expenses include external expenses incurred under arrangements with third parties; salaries and personnel-related costs; license fees to acquire in-process technology and other expenses. The Company recognizes the benefit of refundable R&D tax refunds as a R&D tax refund income when there is reasonable assurance that the amount claimed will be recovered (refer to the R&D tax refund discussion above). Intellectual property acquired for a particular research and development project and that have no alternative future uses (in other research and development projects or otherwise) are expensed in research and development costs at the time the costs are incurred. In certain circumstances, the Company may be required to make advance payments to vendors for goods or services that will be received in the future for use in R&D activities. In such circumstances, the non-refundable advance payments are deferred and capitalized, even when there is no alternative future use for the R&D, until the related goods or services are provided. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense. Equity-Based Compensation Equity-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as an expense on a straight-line basis over the requisite service period, if any, based on the terms of the awards. The fair value of the stock-based payments to employees and nonemployees that are fully vested and non-forfeitable at the grant date is measured by reference to the Company’s stock price and recognized immediately, unless there is a contractual term for services in which case such compensation would be amortized over the contractual term. Employee benefits The costs of short-term employee benefits are recognized as a liability and an expense unless those costs are required to be recognized as part of the cost of inventories or non-current assets. The cost of any unused holiday entitlement is recognized in the period in which the employee’s services are received. Termination benefits are recognized immediately as an expense when the Company is demonstrably committed to terminate the employment of an employee or to provide termination benefits. Income taxes In accordance with the provisions of ASC 740, Income Taxes As of June 30, 2024 and 2023, the Company had no uncertain tax positions that qualified for either recognition or disclosure in the consolidated financial statements. Additionally, the Company had no interest and penalties related to income taxes. The Company accounts for current and deferred income taxes and, when appropriate, deferred tax assets and liabilities are recorded with respect to temporary differences in the accounting treatment of items for financial reporting purposes and for income tax purposes. Where, based on the weight of all available evidence, it is more likely than not that some amount of the recorded deferred tax assets will not be realized, a valuation allowance is established for that amount that, in management’s judgment, is sufficient to reduce the deferred tax asset to an amount that is more likely than not to be realized. Net loss per share attributable to common shareholders (“EPS”) The Company calculates earnings per share attributable to common shareholders in accordance with ASC 260, Earning Per Share Potentially dilutive common stock are calculated in accordance with the treasury share method, which assumes that proceeds from the exercise of all warrants are used to repurchase common stock at market value. The number of shares remaining after the proceeds are exhausted represents the potentially dilutive effect of the securities. As the Company has incurred net losses in all periods, certain potentially dilutive securities, including convertible preferred stock, warrants to acquire common stock, and convertible notes payable have been excluded in the computation of diluted loss per share as the effects are antidilutive. Recent accounting pronouncements As the Company is an emerging growth company, we have elected to defer the adoption of new accounting pronouncements until they would apply to private companies. Adopted: Financial Instruments – Credit Losses (“ASU 2016-13”) In June 2016, the FASB issued ASU No. 2016-13 (Topic 326), Financial Instruments – Credit Losses Pending adoption: Business Combinations (Topic 805) – Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”) In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805) – Accounting for Contract Assets and Contract Liabilities from Contracts with Customers Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”) In November 2023, the FASB issued ASU 2023-07 to enhance disclosures about significant segment expenses. The amendments in this ASU require a public entity to disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment’s profit or loss and assets that are currently required annually. The amendments in this ASU also clarify circumstances in which an entity can disclose multiple segment measures of profit or loss and provide new segment disclosure requirements for entities with a single reportable segment. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. Early adoption is permitted. The ASU is to be applied retrospectively to all periods presented in the financial statements. The Company has not early adopted and continues to evaluate the impact of the provisions of ASU 2023-07 on its consolidated financial statements. Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”) In December 2023, the FASB issued ASU 2023-09 to enhance disclosures about income taxes. The amendments in this ASU require a public entity to disclose in tabular format, using both percentages and reporting currency amounts, specific categories in the rate reconciliation and to provide additional information for reconciling items that meet a quantitative threshold. The amendments in this ASU also require taxes paid (net of refunds received) to be disaggregated by federal, state, and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold. The ASU is effective for fiscal years beginning after December 15, 2025, with early adoption permitted. The ASU is to be applied prospectively upon adoption. The Company has not early adopted and continues to evaluate the impact of the provisions of ASU 2023-09 on its consolidated financial statements.

SEGMENT REPORTING

SEGMENT REPORTING	12 Months Ended
	Jun. 30, 2024
Segment Reporting [Abstract]
SEGMENT REPORTING	NOTE 4. SEGMENT REPORTING ASC 280, Segment Reporting Our Segments Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s CODM is its Chief Executive Officer. Following the acquisition of IFP, we conduct our business through two operating segments: 1) Commercially available Intelligent Fingerprinting Products (IFPG or IFPG segment) 2) Development Stage Biosensor Platform Technology (BPT segment) The Company has determined it operates in two operating and reportable segments, as the CODM reviews financial information presented on a consolidated basis accompanied by disaggregated information about revenue and other income by product types for the purpose of allocating resources and evaluating financial performance. Currently, the Company has two products offerings. The IFPG segment accounted for 100% of the Company’s revenue during the year ended June 30, 2024 and 2023. The following tables set forth the Company’s revenue, government support income, net loss and long-lived assets and inventories by operating and reportable segments. SCHEDULE OF REVENUE, GOVERNMENT SUPPORT INCOME, NET LOSS AND LONG LIVED ASSETS AND INVENTORIES A) Revenue, government support income and net loss IFPG BPT Total Year Ended June 30, 2024 IFPG BPT Total Revenue United Kingdom $ 2,597,264 $ - $ 2,597,264 Australia 43,955 - 43,955 Other 470,562 - 470,562 Total Revenue $ 3,111,781 $ - $ 3,111,781 Government Support Income United Kingdom 210,605 - 210,605 Australia - 214,171 214,171 Total Government Support Income $ 210,605 $ 214,171 $ 424,776 Total Revenue and Government Support Income $ 3,322,386 $ 214,171 $ 3,536,557 Net Loss $ (2,992,228 ) $ (7,198,704 ) $ (10,190,932 ) IFPG BPT Total Year Ended June 30, 2023 IFPG BPT Total Revenue United Kingdom $ 1,061,191 $ - $ 1,061,191 Australia 6,491 - 6,491 Other 189,190 - 189,190 Total Revenue $ 1,256,872 $ - $ 1,256,872 Government Support Income United Kingdom 193,618 - 193,618 Australia - 544,010 544,010 Total Government Support Income $ 193,618 $ 544,010 $ 737,628 Total Revenue and Government Support Income $ 1,450,490 $ 544,010 $ 1,994,500 Net Loss $ (5,260,588 ) $ (5,403,967 ) $ (10,664,555 ) B) Long-lived assets and inventories IFPG BPT Total June 30, 2024 IFPG BPT Total Long-lived assets, net United Kingdom $ 4,626,798 $ - $ 4,626,798 Australia - 617,822 617,822 Total Long-Lived Assets $ 4,626,798 $ 617,822 $ 5,244,620 Inventories, net United Kingdom 731,813 - 731,813 Australia 45,724 - 45,724 Total Inventories $ 777,537 $ - $ 777,537 Total Long-Lived Assets and Inventories, net $ 5,404,335 $ 617,822 $ 6,022,157 IFPG BPT Total June 30, 2023 IFPG BPT Total Long-lived assets, net United Kingdom $ 5,730,831 $ - $ 5,730,831 Australia - 761,220 761,220 Total Long-Lived Assets $ 5,730,831 $ 761,220 $ 6,492,051 Inventories, net United Kingdom 880,696 - 880,696 Australia 99,211 - 99,211 Total Inventories $ 979,907 $ - $ 979,907 Total Long-Lived Assets and Inventories, net $ 6,710,738 $ 761,220 $ 7,471,958

INTELLIGENT FINGERPRINTING LIMI

INTELLIGENT FINGERPRINTING LIMITED ACQUISITION	12 Months Ended
	Jun. 30, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
INTELLIGENT FINGERPRINTING LIMITED ACQUISITION	NOTE 5. INTELLIGENT FINGERPRINTING LIMITED ACQUISITION On October 4, 2022, INBS acquired 100 The table below summarizes the fair value of the consideration transferred in the acquisition (pre-Company’s Reverse Stock Splits): SCHEDULE OF FAIR VALUE OF THE CONSIDERATION TRANSFERRED IN THE ACQUISITION Purchase consideration * Amount Cash $ 363,500 Note receivable settled for business acquisition 504,938 Common Stock - 2,963,091 0.5502 1,630,293 Series C Preferred Stock (base) - 2,363,003 0.5502 3,900,373 Series C Preferred Stock (holdback) - 500,000 0.5502 825,300 Purchase consideration of Common Stock and Series C Preferred Stock 825,300 Total purchase price $ 7,224,404 * The description of the IFP Acquisition below this table describes the purchase consideration on a post-Company’s Reverse Stock Splits basis. Pursuant to the Share Exchange Agreement, the Company acquired from the IFP Sellers all of the issued and outstanding shares of the capital stock of IFP, and as consideration therefore, the Company issued and sold to the IFP Sellers upon the closing of the IFP Acquisition (the “IFP Closing”) an aggregate number of 12,347 2,363,003 0.01 Up to an additional 1,649,273 500,000 1,149,273 0.0125 Effective contemporaneously with the IFP Closing, the Company entered into an amendment to the bridge facility agreement between the Company and IFP, dated as of June 16, 2022, pursuant to which, among other things, the $ 504,938 The loan receivable from IFP of $ 504,938 Business Combinations The Company entered into various loan agreements in the aggregate amount of $ 1,425,307 1,254,270 17 22 Each share of Series C Preferred Stock (other than the IFP Lender Preferred Shares) automatically converted into common stock upon approval of the Company’s stockholders of the conversion of Series C Preferred Stock into common stock, and each IFP Lender Preferred Share converted into common stock at the option of the applicable holder of such IFP Lender Preferred Shares following approval of the Company’s stockholders of the conversion of Series C Preferred Stock into common stock. The number of shares of common stock into which the Series C Preferred Stock was convertible was subject to adjustment in the case of any stock dividend, stock split, combinations, or other similar recapitalization with respect to the common stock. The rights, preferences and privileges of the Series C Preferred Stock are set forth in the Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock that the Company filed with the Secretary of State of the State of Delaware on October 4, 2022, as further described below (the “Series C Certificate of Designation”). The Series C Preferred Stock does not have any voting rights (other than as required by law) and does not carry dividends or a liquidation preference. Each share of Series C Preferred Stock was initially convertible into 3 shares of common stock, subject to adjustment as noted above. Following the Company’s Reverse Stock Splits, each share of Series C Preferred Stock was convertible into 0.0125 504,938 The Company incurred $ 806,397 At the Special Meeting on May 8, 2023, the last of the remaining Company Stockholder Approval Matters were approved when the Company’s stockholders approved the full conversion of all Series C Preferred Stock and an increase in the number of shares authorized for issuance under the 2019 Long Term Incentive Plan (“2019 Plan” or the “Plan”). Subsequently, effective as of May 10, 2023, all 3,512,277 1,149,273 500,000 43,902 The 500,000 500,000 6,248 The final allocation of the purchase price of IFP to the assets acquired and liabilities assumed, based on their relative fair values, is as follows: SCHEDULE OF ASSETS ACQUIRED AND LIABILITIES ASSUMED, BASED ON THEIR RELATIVE FAIR VALUES Allocation of purchase consideration Amount Assets: Cash and cash equivalents $ 174,481 Inventory 774,625 Other current assets 345,038 Property and Equipment 52,170 Intangible assets 5,463,000 Goodwill 3,803,293 Total assets acquired 10,612,607 Liabilities: Accounts payable and accrued expenses (1,027,302 ) Notes payable (677,137 ) Convertible notes payable (1,683,764 ) Total liabilities assumed (3,388,203 ) Net assets $ 7,224,404 Acquired intangible assets of $ 5,463,000 5,119,000 7 252,000 3 92,000 During the fiscal year ended June 30, 2023, the full amount of goodwill was impaired. Transaction costs, except for the equity issuance costs discussed above, were not material and are included in selling, general and administrative expenses on the Company’s consolidated statement of operations. Intangible assets acquired from IFP were remeasured at June 30, 2024 and 2023 using the applicable spot rate. Pro-Forma Results of Operations Unaudited pro-forma consolidated results of operations for the year ended June 30, 2024, is not required because the results of the acquired business are included in the Company’s results. The following unaudited pro-forma consolidated results of operations for the year ended June 30, 2023, has been prepared as if the acquisition of IFP had occurred on July 1, 2022 and includes adjustments for amortization related to the valuation of acquired intangibles: SCHEDULE OF UNAUDITED PRO-FORMA CONSOLIDATED RESULTS OF OPERATIONS Reported Pro forma Year Ended June 30, 2023 Reported Pro forma Revenue $ 1,256,872 $ 1,604,358 Net loss (10,664,555 ) (11,906,109 ) Net loss attributable to Intelligent Bio Solutions Inc. (10,631,720 ) (11,873,274 ) Net loss per share, basic and diluted (127.00 ) (141.84 )

INVENTORIES, NET

INVENTORIES, NET	12 Months Ended
	Jun. 30, 2024
Inventory Disclosure [Abstract]
INVENTORIES, NET	NOTE 6. INVENTORIES, NET Inventories consist of the following: SCHEDULE OF INVENTORIES June 30, 2024 June 30, 2023 Raw material /Work-in-progress $ 188,693 $ 419,889 Finished goods 588,844 757,518 Less: provision for inventory obsolescence - (197,500 ) Inventories, net $ 777,537 $ 979,907

OTHER CURRENT ASSETS

OTHER CURRENT ASSETS	12 Months Ended
	Jun. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
OTHER CURRENT ASSETS	NOTE 7. OTHER CURRENT ASSETS Other current assets consist of the following: SCHEDULE OF OTHER CURRENT ASSETS June 30, 2024 June 30, 2023 Prepayments $ 363,071 $ 359,953 Goods and services tax receivable 17,011 20,418 Deposits 111,189 118,193 Deferred charges - 34,100 Other receivables 6,301 20,127 Total $ 497,572 $ 552,791

PROPERTY AND EQUIPMENT, NET

PROPERTY AND EQUIPMENT, NET	12 Months Ended
	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT, NET	NOTE 8. PROPERTY AND EQUIPMENT, NET Property and equipment consist of the following: SCHEDULE OF PROPERTY AND EQUIPMENT June 30, 2024 June 30, 2023 Production equipment $ 35,724 $ 30,348 Leasehold improvements 20,074 20,069 Other equipment 27,417 27,411 Construction in progress (CIP) 543,410 646,116 Gross property and equipment 626,625 723,944 Less: accumulated depreciation and amortization (60,775 ) (33,769 ) Property and equipment, net $ 565,850 $ 690,175 The Company recorded expense of $ 15,108 33,769 The Company incurred no costs toward the construction of a building at the University of Newcastle during the year ended June 30, 2024, compared to a total of $ 509,416 50 The following table summarizes the amount of CIP recorded in property and equipment, net on the consolidated balance sheets: SUMMARY OF AMOUNT RECORDED IN THE CONSOLIDATED BALANCE SHEETS June 30, 2024 June 30, 2023 Investments in construction in progress $ 1,086,820 $ 1,292,232 Less: 50% contributed under government grant (543,410 ) (646,116 ) Carrying amount $ 543,410 $ 646,116

INTANGIBLE ASSETS, NET

INTANGIBLE ASSETS, NET	12 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS, NET	NOTE 9. INTANGIBLE ASSETS, NET Intangible assets, net consist of the following as June 30, 2024: SCHEDULE OF OTHER INTANGIBLE ASSETS Weighted Acquisition Effect of Accumulated Carrying Technology 7 years $ 5,119,000 $ 593,026 $ 1,559,822 $ 4,152,204 Customer relationships 3 years 252,000 29,194 164,030 117,164 Trade names and trademarks Indefinite 92,000 10,658 - 102,658 Total intangible assets $ 5,463,000 $ 632,878 $ 1,723,852 $ 4,372,026 Intangible assets, net consist of the following as of June 30, 2023: Weighted Acquisition Effect of Accumulated Carrying Technology 7 years $ 5,119,000 $ 603,422 $ 780,500 $ 4,941,922 Customer relationships 3 years 252,000 29,127 70,282 210,845 Trade names and trademarks Indefinite 92,000 10,634 - 102,634 Total intangible assets $ 5,463,000 $ 643,183 $ 850,782 $ 5,255,401 Intangible assets recognized from the acquisition of IFP were allocated to the IFPG operating and reportable segment. The cumulative balance of the accumulated amortization as of June 30, 2024 and 2023 was $ 1,723,852 850,782 Expense related to the amortization of intangible assets charged to the Consolidated Statements of Operations and Other Comprehensive Income (Loss) for the years ended June 30, 2024 and 2023 was $ 947,436 805,764 Amortization expense for the intangible assets is expected to be as follows over the next five years, and thereafter: SCHEDULE OF EXPECTED AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS 2025 $ 884,627 2026 814,329 2027 790,896 2028 790,896 2029 790,896 Thereafter 197,724 Total $ 4,269,368

ACCOUNTS PAYABLE AND ACCRUED EX

ACCOUNTS PAYABLE AND ACCRUED EXPENSES	12 Months Ended
	Jun. 30, 2024
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	NOTE 10. ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses consist of the following: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES June 30, 2024 June 30, 2023 Accounts and other payables $ 602,337 $ 1,196,222 Accruals 607,176 777,086 Deferred consideration * - 208,500 Goods and services tax payable 50,283 - Accrued compensation and related payables 444,772 428,220 Total $ 1,704,568 $ 2,610,028 * Deferred consideration relates to the fair value of $ 208,500 500,000 500,000 6,248

NOTE PAYABLE

NOTE PAYABLE	12 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
NOTE PAYABLE	NOTE 11. NOTE PAYABLE As a result of the acquisition of IFP, the Company assumed a note payable due to a distributor of IFP. The unpaid principal balance of the loan will accrue interest at a rate of 0.97 ● Payments of 10 ● 50 The classification of the notes payables is based on sales forecast prepared by the management.

LEASES

LEASES	12 Months Ended
	Jun. 30, 2024
Leases [Abstract]
LEASES	NOTE 12. LEASES The Company assumed a non-cancellable operating lease agreement in relation to IFP Acquisition on October 4, 2022. Additionally, the Company also entered into another non-cancellable operating lease that commenced in May 2023. The leases have original lease periods expiring from August 2025 to April 2026. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. The components of operating lease expense are as follows: SCHEDULE OF LEASE EXPENSES 2024 2023 Year Ended June 30, 2024 2023 Amortization of operating lease right-of-use assets $ 238,730 $ 152,251 Interest on operating lease liabilities 71,667 68,357 Total operating lease costs $ 310,397 $ 220,608 As of June 30, 2024, the weighted average remaining lease-term and discount rate on the Company’s leases were 1.3 13.2 As of June 30, 2023, the weighted average remaining lease-term and discount rate on the Company’s leases were 2.3 13.2 The reconciliation of the maturities of the operating leases to the operating lease liabilities recorded in the consolidated balance sheet as of June 30, 2024, is as follows: SCHEDULE OF MATURITIES OF OPERATING LEASES TO OPERATING LEASE LIABILITIES 2025 $ 308,770 2026 83,509 Total lease payments 392,279 Less: imputed interest (36,121 ) Present value of lease liabilities $ 356,158

SHAREHOLDERS_ EQUITY

SHAREHOLDERS’ EQUITY	12 Months Ended
	Jun. 30, 2024
Equity [Abstract]
SHAREHOLDERS’ EQUITY	NOTE 13. SHAREHOLDERS’ EQUITY As of June 30, 2024, there were warrants outstanding to purchase shares amounting to 6,310,684 The Company accounts for warrants in accordance with the guidance contained in ASC 815-40, Derivatives and Hedging - Contracts on an Entity’s Own Equity, and determined that the warrants do not meet the criteria for liability treatment thereunder. March 2024 Private Placement On March 8, 2024, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with several institutional and accredited investors for the sale by the Company of (i) 675,183 1,548,150 2,223,333 2,223,333 4.55 Subject to certain ownership limitations, the March Warrants are exercisable upon issuance. Each Pre-Funded Warrant is exercisable into one share of common stock at a price per share of $ 0.01 4.55 5 The gross proceeds to the Company from the March 2024 Offering were approximately $ 10.10 In connection with the Purchase Agreement, the Company entered in a Registration Rights Agreement and agreed to file by March 18, 2024, a resale registration statement (the “Resale Registration Statement”) with the SEC covering all shares of common stock sold to investors and the shares of common stock issuable upon exercise of the March Warrants, which was effective as of March 28, 2024. The Shares, the March Warrants, and the shares issuable upon exercise of the March Warrants were sold and issued without registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and Rule 506 of Regulation D promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws. On March 8, 2024, the Company entered into a Placement Agency Agreement with Ladenburg Thalmann & Co. Inc. (the “Agent”) pursuant to which the Company agreed to pay the Agent (i) a cash fee equal to 8.0% of the gross proceeds received by the Company in the March 2024 Offering, (ii) a management fee equal to 1.0% of the gross proceeds received by the Company in the March 2024 Offering, (iii) common stock purchase warrants to purchase such number of shares of common stock equal to 5% of the aggregate number Shares and Pre-Funded Warrants sold in the March 2024 Offering, which warrants are to have an exercise price equal to 125% of the offering price per share and an expiration date of 5 years from issuance (the “Placement Agent Warrants”); (iv) a cash fee equal to 9.0% of the gross proceeds received by the Company from the cash exercise of any H-1 Warrants and H-2 Warrants; and (vi) reimbursement of the Agent’s expenses in an amount up to $ 145,000 Warrant Inducement Transaction On February 4, 2024, the Company entered into warrant inducement agreements (the “Inducement Agreements”) with certain accredited and institutional holders (collectively, the “Holders”) of the Company’s outstanding Series E Warrants issued on October 4, 2023 (the “Series E Warrants”). Pursuant to the Inducement Agreements, each Holder that exercised its Series E Warrants pursuant to the Inducement Agreement received one (1) replacement warrant (a “Series G Warrant”) for each Series E Warrant exercised (the “Warrant Inducement Transaction”). The Series E Warrants had an exercise price of $ 2.9232 5.5 4.50 The closing of the Warrant Inducement Transaction took place on February 7, 2024. Gross proceeds to the Company from the exercise of the Series E Warrants was approximately $ 1.77 606,064 The issuance of the Series G Warrants was made in reliance upon an exemption from the registration requirements pursuant to Section 4(a)(2) of the Securities Act. October 2023 Offering On October 4, 2023, the Company completed an underwritten public offering of its securities in the form of units (the “October 2023 Offering”) consisting a total of 2,232,221 186,018 5,728,723 7,960,944 663,412 five-and-a-half-year 7,960,944 663,412 0.55 4.38 3.79 The original exercise price of the Series E Warrants was $ 0.55 6.60 (i) the then exercise price and (ii) 90% of the five-day volume weighted average price for the five trading days immediately following the date the Company effects a reverse stock split. As a result of the January 2024 Reverse Stock Split, the exercise price of the Series E Warrants was reset to $ 2.9232 0.55 6.60 The Company also agreed to issue to the Underwriters, warrants to purchase up to 5.0 398,047 33,171 0.6875 8.25 Also on October 4, 2023, following the one-year anniversary of the IFP Acquisition, the Company issued 74,971 6,248 500,000 0.15 0.0125 Subsequent to the October 2023 Offering, all 5,728,723 5,728,723 477,394 7,346,178 612,182 Stock-based payments under 2019 Stock Incentive Plan The 2019 Long Term Incentive Plan, the 2019 Stock Incentive Plan, was originally adopted by the Board and approved by the Company’s stockholders on June 18, 2019. The purpose of the 2019 Stock Incentive Plan is to enable the Company to offer its employees, officers, directors and consultants whose past, present and/or potential future contributions have been, are, or will be important to the Company’s success. Under the 2019 Stock Incentive Plan the Company may grant certain employees, consultants and advisors an award, such as (a) incentive stock options, (b) non-qualified stock options, (c) stock appreciation rights (d) restricted stock and (e) RSUs, of the Company. The 2019 Plan is administered by the Board of Directors or by a committee of the Board. As approved by the Company’s board and stockholders, the third plan amendment provides for 133,333 On February 29, 2024, the Company entered into a Consulting Agreement (the “C2C Agreement”) with C2C Advisors Inc. (“C2C”) pursuant to which C2C will provide certain advisory and investor relations services to the Company. As consideration for such services, the Company agreed to pay a fee consisting of: (a) a cash fee of $ 25,000 37,500 179,625 On February 29, 2024, the Company entered into an Investor Relations and Corporate Development Advisory Agreement (the “ClearThink Agreement”) with ClearThink Capital LLC (“ClearThink”) pursuant to which ClearThink provides certain advisory and investor relations services to the Company. As consideration for such services, the Company agreed pay a fee consisting of: (a) an initial grant of 5,260 5,000 4,000 12,000 25,195 During the year ended June 30, 2024, the Company granted 5,762 3.40 19,578

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 14. FAIR VALUE MEASUREMENTS Convertible notes The Company held back 500,000 0.0125 Effective one year after the IFP Closing, the 500,000 6,248 See Note 5 for further information and disclosures relating to the conversion of the Series C Preferred Stock, including the Closing Holdback Shares. The following table provides a reconciliation of the beginning and ending balance of the Closing Holdback Shares (in the form of Series C Preferred Stock) measured at fair value on a recurring basis during the period: SCHEDULE OF CLOSING HOLDBACK SHARES OF SERIES C PREFERRED STOCK AT FAIR VALUE ON RECURRING Preferred stock Balance at June 30, 2022 $ - Fair value of holdback Series C Preferred Stock at acquisition (Note 5) 825,300 Fair value gain on revaluation of holdback Series C Preferred Stock (616,800 ) Balance at June 30, 2023 208,500 Fair value gain on revaluation of holdback Series C Preferred Stock (175,738 ) Conversion of Series C Preferred Stock into Common Stock (32,762 ) Balance at June 30, 2024 $ - The Company did not have assets or liabilities carried at fair value using Level 1 inputs as of June 30, 2024 and 2023. The Company did not have assets or liabilities carried at fair value using Level 3 inputs as of June 30, 2024 and 2023. The Company has not transferred any assets between fair value measurement levels during the years ended June 30, 2024 and 2023.

RELATED-PARTY TRANSACTIONS

RELATED-PARTY TRANSACTIONS	12 Months Ended
	Jun. 30, 2024
Related Party Transactions [Abstract]
RELATED-PARTY TRANSACTIONS	NOTE 15. RELATED-PARTY TRANSACTIONS October 2023 Offering Spiro Sakiris, our Chief Financial Officer, purchased 112,727 9,090 0.55

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 16. COMMITMENTS AND CONTINGENCIES On February 9, 2024, the Company signed an agreement with Cliantha Research to conduct a clinical study as a part of the Company’s FDA 510(k) clinical study plan. As a part of the agreement, the Company is committed to pay $ 494,197 197,679 The Company has no material purchase commitments. For commitments under non-cancellable leases, refer to Note 12. From time to time, the Company may become a party to various legal proceedings arising in the ordinary course of business. Based on information currently available, the Company is not involved in any pending or threatened legal proceedings that it believes could reasonably be expected to have a material adverse effect on its financial condition, results of operations or liquidity. However, legal matters are inherently uncertain, and the Company cannot guarantee that the outcome of any potential legal matter will be favorable to the Company.

INCOME TAX

INCOME TAX	12 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
INCOME TAX	NOTE 17. INCOME TAX The Company computes income taxes using the asset and liability method in accordance with FASB ASC Topic 740, Income Taxes $ 10,421,568 9,530,704 , respectively, against deferred tax assets in excess of deferred tax liabilities. The components of net deferred taxes are as follows: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES June 30, 2024 June 30, 2023 Deferred tax assets (liabilities): Net operating loss - U.S. $ $ 3,914,445 Net operating loss - Foreign 6,090,380 5,347,487 Employee benefits 118,132 153,199 Inventory adjustments (1,124 ) 38,034 Foreign exchange 31,902 77,539 Total deferred tax assets, net 10,421,568 9,530,704 Less: valuation allowance (10,421,568 ) (9,530,704 ) Net deferred taxes $ — $ — Our statutory income tax rate is expected to be approximately 21%. The provision for income taxes consisted of the following: SCHEDULE OF PROVISION FOR INCOME TAXES 2024 2023 Year Ended June 30, 2024 2023 Current $ — $ — Deferred — — Total $ — $ — The reconciliation between the income tax expense (benefit) calculated by applying statutory rates to net loss and the income tax expense reported in the accompanying consolidated financial statements is as follows: SCHEDULE OF RECONCILIATION OF INCOME TAX EXPENSE (BENEFIT) 2024 2023 Year Ended June 30, 2024 2023 U.S. federal statutory rate applies to pretax income (loss) $ (1,848,116 ) $ (2,310,635 ) Different tax rate of subsidiary (99,401 ) (18,715 ) Permanent differences 246,168 680,221 Tax benefit on carry forward losses of acquired business - (3,289,886 ) Cumulative adjustment to deferred taxes 797,234 1,681,562 Change in state tax rates and other 13,250 (209,226 ) Change in valuation allowance 890,865 3,466,679 Total income tax provision (benefit) $ — $ — As of June 30, 2024, and 2023, the Company had federal and foreign income tax net operating loss carry forwards of approximately $ 49,097,053 44,492,527 , respectively, which expire at various dates ranging from 2038 through unlimited expiration.

LOSS PER SHARE

LOSS PER SHARE	12 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
LOSS PER SHARE	NOTE 18. LOSS PER SHARE Basic loss per common share is computed by dividing net loss allocable to common shareholders by the weighted average number of shares of common stock or common stock equivalents outstanding after adjusting for the February 2023 Reverse Stock Split, and the January 2024 Reverse Stock Split. Diluted loss per common share is computed similar to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. SCHEDULE OF BASIC LOSS PER COMMON SHARE POTENTIAL DILUTIVE SECURITIES Years Ended June 30, 2024 2023 Net loss attributable to Intelligent Bio Solutions Inc. $ (10,156,759 ) $ (10,631,720 ) Basic and diluted net loss per share attributed to common shareholders $ (6.38 ) $ (127.00 ) Weighted-average number of shares outstanding 1,592,746 83,717 The following outstanding warrants, options and preferred shares were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Post-Consolidated Company Reverse Stock Split: Anti-dilutive warrants SCHEDULE OF ANTI-DILUTIVE WARRANTS 2024 2023 Year Ended June 30, 2024 2023 Warrants 6,310,684 35,547 Anti-dilutive 6,310,684 35,547

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 19. SUBSEQUENT EVENTS No material subsequent events have taken place that require disclosure in this financial report noted between June 30, 2024, and the date of this report.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) as of June 30, 2024 and 2023. The consolidated financial statements and notes thereto give retrospective effect to the stock splits for all periods presented. All common stock, options exercisable for common stock, restricted stock units, warrants and per share amounts contained in the consolidated financial statements have been retrospectively adjusted to reflect the stock splits for all periods presented.
Principles of consolidation	Principles of consolidation These consolidated financial statements include the accounts of the Company, all wholly owned and majority-owned subsidiaries in which the Company has a controlling voting interest and, when applicable, variable interest entities in which the Company has a controlling financial interest or is the primary beneficiary. Investments in affiliates where the Company does not exert a controlling financial interest are not consolidated. All significant intercompany transactions and balances have been eliminated upon consolidation.
Foreign currency translation	Foreign currency translation Assets and liabilities of foreign subsidiaries are translated from local (functional) currency to reporting currency (U.S. dollar) at the spot rate on the consolidated balance sheets date; income and expenses are translated at the average rate of exchange prevailing during the year. Adjustments resulting from translating local currency financial statements into U.S. dollars are reflected in accumulated other comprehensive loss in total shareholders’ equity. The functional currency of INBS is the United States dollar. The settlement of transactions denominated in a currency other than the functional currency resulted in a loss of $ 137,118 212,639
Use of estimates	Use of estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Significant estimates made by management in connection with the preparation of the accompanying consolidated financial statements including the fair value measurement of and the useful lives of long-lived assets, inventory valuations, the allocation of transaction price among various performance obligations, and the allowance for credit losses. Actual results could materially differ from those estimates.
Risks and Uncertainties	Risks and Uncertainties The Company’s future results of operations and liquidity could be materially adversely affected by macroeconomic factors contributing to delays in payments from customers and inflationary pressure, uncertain or reduced demand, and the impact of any initiatives or programs that the Company may undertake to address financial and operational challenges faced by its customers. See associated risk factors in Item 1A. Risk Factors in Item 1A Risk Factors in this Annual Report on Form 10-K.
Cash and cash equivalents	Cash and cash equivalents The Company considers all highly liquid investments with a maturity of 90 days or less to be cash equivalents. The carrying values of cash and cash equivalents approximate their fair values due to the short-term nature of these instruments. As of June 30, 2024 and 2023, there were no
Concentration of credit risk	Concentration of credit risk The Company places its cash and cash equivalents, which may at times be in excess of the Australia Financial Claims Scheme, Financial Services Compensation Scheme or the United States’ Federal Deposit Insurance Corporation insurance limits, with high credit quality financial institutions and attempts to limit the amount of credit exposure with any one institution. The amounts over these insured limits as of June 30, 2024 and 2023 were $ 5,781,130 1,114,687
Fair value measurements	Fair value measurements The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1 Level 2 Level 3 Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The carrying amounts of cash equivalents, prepaid and other assets, accounts payable and accrued liabilities are representative of their respective fair values because of the short-term nature of those instruments.
Inventories, net	Inventories, net Inventories are stated at the lower of cost or net realizable value. Cost comprises direct materials and, where applicable, other costs that have been incurred in bringing the inventories to their present location and condition. Net realizable value is the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution. General market conditions, as well as the Company’s research activities, can cause certain of its products to become obsolete. The Company writes down excess and obsolete inventories based upon a regular analysis of inventory on hand compared to historical and projected demand. The determination of projected demand requires the use of estimates and assumptions related to projected sales for each product. These write downs can influence results from operations.
Equity offering costs	Equity offering costs The Company complies with the requirements of Accounting Standards Codification (“ASC”) 340, Other Assets and Deferred Costs
Property, Plant and Equipment (“PPE”) & Construction in Progress (“CIP”)	Property, Plant and Equipment (“PPE”) & Construction in Progress (“CIP”) In accordance with the ASC 360, Property, Plant, and Equipment ● Other equipment – 3 ● Production equipment – 2 4 ● Leasehold improvements – shorter of asset’s estimated useful life and the remaining term of the lease The assets’ residual values, useful lives and methods of depreciation are reviewed periodically and adjusted prospectively, if appropriate. Equipment is derecognized upon disposal or when no future economic benefits are expected from its use. Any gain or loss arising upon de-recognition of the asset (calculated as the difference between the net disposal proceeds, if any, and the carrying value of the asset) is included in gain or loss on sale of assets in the consolidated statements of operations in the period the asset is derecognized.
Leases	Leases The Company determines if an arrangement is a lease at its inception. Lease arrangements are comprised primarily of real estate for which the right-of-use (“ROU”) assets and the corresponding lease liabilities are presented separately on the consolidated balance sheet. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The lease term includes options to extend the lease when it is reasonably certain that the option will be exercised. Leases with a term of 12 months or less are not recorded on the consolidated balance sheet. The Company uses its estimated incremental borrowing rate in determining the present value of lease payments considering the term of the lease, which is derived from information available at the lease commencement date, considering publicly available data for instruments with similar characteristics. The Company accounts for the lease and non-lease components as a single lease component.
Intangible assets	Intangible assets Intangible assets are considered long-lived assets and are recorded at cost, less accumulated amortization and impairment losses, if any. The definite-lived intangible assets are amortized over their estimated useful lives, which do not exceed any contractual periods. Certain of our intangible assets have been assigned an indefinite life as we currently anticipate that these trade names and trademarks will contribute cash flows to the Company indefinitely. Indefinite-lived intangible assets are not amortized but are evaluated at least annually to determine whether the indefinite useful life is appropriate. Amortization is recorded on a straight-line basis over their estimated useful lives. Intangible assets acquired from a foreign operation are translated from the foreign entity’s functional currency to the presentational currency based on the exchange rate at the reporting date.
Impairment of long-lived assets	Impairment of long-lived assets Long-lived assets include acquired property and equipment, right of use assets and other intangible assets subject to amortization. The Company evaluates the recoverability of long-lived assets for possible impairment whenever events or changes in circumstances indicate that the related carrying amount may not be recoverable. Such events and changes may include significant changes in performance relative to expected operating results, significant changes in asset use, significant negative industry or economic trends, and changes in the Company’s business strategy. Recoverability is measured by a comparison of the carrying amount of an asset or asset group to the undiscounted future cash flows expected to be generated by the asset or asset group. When required, impairment losses on assets to be held and used are recognized based on the excess of the asset’s carrying amount over the fair value of the asset, while long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. During the fiscal year ended June 30, 2023, the Company recognized an impairment charge of $ 4.2 million in the IFPG segment, which is related to the goodwill associated with the IFP Acquisition. Following the impairment charge the goodwill balance was zero. For the year ended June 30, 2024, the Company did not record any impairment charges on its long-lived assets.
Business combinations	Business combinations The results of businesses acquired in a business combination are included in the Company’s consolidated financial statements from the date of the acquisition. The Company uses the acquisition method of accounting and allocates the purchase price to the identifiable assets and liabilities of the relevant acquired business at their acquisition date fair values. Any excess consideration over the fair value of assets acquired and liabilities assumed is recognized as goodwill. The allocation of the purchase price in a business combination requires the Company to perform valuations with significant judgment and estimates, including the selection of valuation methodologies, estimates of future revenue, costs and cash flows, discount rates and selection of comparable companies. The Company engages the assistance of valuation specialists in concluding on fair value measurements in connection with determining fair value of assets acquired and liabilities assumed in a business combination. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company records adjustments to the assets acquired and liabilities assumed with a corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statements of operations. Transaction costs associated with business combinations are expensed as incurred and are included in selling, general and administrative expenses in the consolidated statements of operations.
Revenue recognition	Revenue recognition In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue from its contracts with customers when it satisfies its performance obligations by delivering the promised goods or service deliverables to the customers. A good or service deliverable is transferred to a customer when, or as, the customer obtains control of the good or service deliverable. Financial information presented on a consolidated basis is accompanied by disaggregated information about revenue and other income by product type for the purpose of allocating resources and evaluating financial performance. Currently, the Company has two products offerings. Accordingly, the Company has determined the following reporting segments (refer to Note 4, Segment Information): 1) Commercially available Intelligent Fingerprinting Products (“IFPG” or “IFPG segment”) 2) Development Stage Biosensor Platform Technology (“BPT segment”) Revenue is used to evaluate the performance of the Company’s segments, the progress of major initiatives and the allocation of resources. All of the Company’s revenues is attributable to the IFPG segment during the years ended June 30, 2024 and 2023. Revenue from the IFPG segment relates to the sale of readers, cartridges and other sales which represents accessories and is summarized as follows: SCHEDULE OF REVENUE SALES OF READERS CARTRIDGES AND OTHER SALES WHICH REPRESENTS ACCESSORIES 2024 2023 Year ended June 30, 2024 2023 Sales of goods - cartridges $ 1,549,409 $ 724,304 Sales of goods - readers 938,897 335,863 Other sales 623,475 196,705 Total revenue $ 3,111,781 $ 1,256,872
Other income	Other income The other income is mainly comprised of grant income and Research & Development (“R&D”) tax refund. a) Grant income On June 30, 2021, the Company executed a definitive grant agreement with the Australian Government to assist with building a manufacturing facility. The grant has a total value of up to $ 4.7 Accounting for the grant does not fall under ASC 606, Revenue from Contracts with Customers Accounting for Government Grants and Disclosure of Government Assistance Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance The Australian Government grant proceeds, which will be used to reimburse construction costs incurred, meet the definition of grants related to assets as the primary purpose for the payments is to fund the construction of a capital asset. Pursuant to IAS 20, the Company has elected to record the grants received initially as deferred income and deduct the grant proceeds received from the gross costs of the assets or construction in progress (“CIP”) and the deferred grant income liability. A total of $ 543,410 646,116 Under IAS 20, government grants are initially recognized when there is reasonable assurance the conditions of the grant will be met and the grant will be received. As of June 30, 2021, management concluded that there was reasonable assurance the grant conditions will be met and all milestone payments received. The total grant value of $ 4.7 1.65 After initial recognition, under IAS 20, government grants are recognized in earnings on a systematic basis in a manner that mirrors the manner in which the Company recognizes the underlying costs for which the grant is intended to compensate. Pursuant to IS 20, the Company has elected to recognize government grant income separately within other income for operating expenditures. Similarly, for capital expenditures, the carrying amount of assets purchased or constructed out of the grant funds are presented net by deducting the grant proceeds received from the gross costs of the assets or CIP and deferred grant income liability. There was no deferred grant income recognized within other income during the year ended June 30, 2024. A total of $ 127,944 deferred grant income was recognized within other income during the year ended June 30, 2023. b) R&D tax refund The Company measures the R&D grant income and receivable by considering the time spent by employees on eligible R&D activities and R&D costs incurred to external service providers. The R&D tax refund receivable is recognized when it is probable that the amount will be recovered in full through a future claim. A total of $ 424,776 609,684
Development and regulatory approval costs	Development and regulatory approval costs Expenditures relating to R&D are expensed as incurred and recorded in development and regulatory approval in the consolidated statements of operations and other comprehensive loss. R&D expenses include external expenses incurred under arrangements with third parties; salaries and personnel-related costs; license fees to acquire in-process technology and other expenses. The Company recognizes the benefit of refundable R&D tax refunds as a R&D tax refund income when there is reasonable assurance that the amount claimed will be recovered (refer to the R&D tax refund discussion above). Intellectual property acquired for a particular research and development project and that have no alternative future uses (in other research and development projects or otherwise) are expensed in research and development costs at the time the costs are incurred. In certain circumstances, the Company may be required to make advance payments to vendors for goods or services that will be received in the future for use in R&D activities. In such circumstances, the non-refundable advance payments are deferred and capitalized, even when there is no alternative future use for the R&D, until the related goods or services are provided. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.
Equity-Based Compensation	Equity-Based Compensation Equity-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as an expense on a straight-line basis over the requisite service period, if any, based on the terms of the awards. The fair value of the stock-based payments to employees and nonemployees that are fully vested and non-forfeitable at the grant date is measured by reference to the Company’s stock price and recognized immediately, unless there is a contractual term for services in which case such compensation would be amortized over the contractual term.
Employee benefits	Employee benefits The costs of short-term employee benefits are recognized as a liability and an expense unless those costs are required to be recognized as part of the cost of inventories or non-current assets. The cost of any unused holiday entitlement is recognized in the period in which the employee’s services are received. Termination benefits are recognized immediately as an expense when the Company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.
Income taxes	Income taxes In accordance with the provisions of ASC 740, Income Taxes As of June 30, 2024 and 2023, the Company had no uncertain tax positions that qualified for either recognition or disclosure in the consolidated financial statements. Additionally, the Company had no interest and penalties related to income taxes. The Company accounts for current and deferred income taxes and, when appropriate, deferred tax assets and liabilities are recorded with respect to temporary differences in the accounting treatment of items for financial reporting purposes and for income tax purposes. Where, based on the weight of all available evidence, it is more likely than not that some amount of the recorded deferred tax assets will not be realized, a valuation allowance is established for that amount that, in management’s judgment, is sufficient to reduce the deferred tax asset to an amount that is more likely than not to be realized.
Net loss per share attributable to common shareholders (“EPS”)	Net loss per share attributable to common shareholders (“EPS”) The Company calculates earnings per share attributable to common shareholders in accordance with ASC 260, Earning Per Share Potentially dilutive common stock are calculated in accordance with the treasury share method, which assumes that proceeds from the exercise of all warrants are used to repurchase common stock at market value. The number of shares remaining after the proceeds are exhausted represents the potentially dilutive effect of the securities. As the Company has incurred net losses in all periods, certain potentially dilutive securities, including convertible preferred stock, warrants to acquire common stock, and convertible notes payable have been excluded in the computation of diluted loss per share as the effects are antidilutive.
Recent accounting pronouncements	Recent accounting pronouncements As the Company is an emerging growth company, we have elected to defer the adoption of new accounting pronouncements until they would apply to private companies. Adopted: Financial Instruments – Credit Losses (“ASU 2016-13”) In June 2016, the FASB issued ASU No. 2016-13 (Topic 326), Financial Instruments – Credit Losses Pending adoption: Business Combinations (Topic 805) – Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”) In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805) – Accounting for Contract Assets and Contract Liabilities from Contracts with Customers Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”) In November 2023, the FASB issued ASU 2023-07 to enhance disclosures about significant segment expenses. The amendments in this ASU require a public entity to disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment’s profit or loss and assets that are currently required annually. The amendments in this ASU also clarify circumstances in which an entity can disclose multiple segment measures of profit or loss and provide new segment disclosure requirements for entities with a single reportable segment. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. Early adoption is permitted. The ASU is to be applied retrospectively to all periods presented in the financial statements. The Company has not early adopted and continues to evaluate the impact of the provisions of ASU 2023-07 on its consolidated financial statements. Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”) In December 2023, the FASB issued ASU 2023-09 to enhance disclosures about income taxes. The amendments in this ASU require a public entity to disclose in tabular format, using both percentages and reporting currency amounts, specific categories in the rate reconciliation and to provide additional information for reconciling items that meet a quantitative threshold. The amendments in this ASU also require taxes paid (net of refunds received) to be disaggregated by federal, state, and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold. The ASU is effective for fiscal years beginning after December 15, 2025, with early adoption permitted. The ASU is to be applied prospectively upon adoption. The Company has not early adopted and continues to evaluate the impact of the provisions of ASU 2023-09 on its consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
SCHEDULE OF REVENUE SALES OF READERS CARTRIDGES AND OTHER SALES WHICH REPRESENTS ACCESSORIES	Revenue from the IFPG segment relates to the sale of readers, cartridges and other sales which represents accessories and is summarized as follows: SCHEDULE OF REVENUE SALES OF READERS CARTRIDGES AND OTHER SALES WHICH REPRESENTS ACCESSORIES 2024 2023 Year ended June 30, 2024 2023 Sales of goods - cartridges $ 1,549,409 $ 724,304 Sales of goods - readers 938,897 335,863 Other sales 623,475 196,705 Total revenue $ 3,111,781 $ 1,256,872

SEGMENT REPORTING (Tables)

SEGMENT REPORTING (Tables)	12 Months Ended
	Jun. 30, 2024
Segment Reporting [Abstract]
SCHEDULE OF REVENUE, GOVERNMENT SUPPORT INCOME, NET LOSS AND LONG LIVED ASSETS AND INVENTORIES	The following tables set forth the Company’s revenue, government support income, net loss and long-lived assets and inventories by operating and reportable segments. SCHEDULE OF REVENUE, GOVERNMENT SUPPORT INCOME, NET LOSS AND LONG LIVED ASSETS AND INVENTORIES A) Revenue, government support income and net loss IFPG BPT Total Year Ended June 30, 2024 IFPG BPT Total Revenue United Kingdom $ 2,597,264 $ - $ 2,597,264 Australia 43,955 - 43,955 Other 470,562 - 470,562 Total Revenue $ 3,111,781 $ - $ 3,111,781 Government Support Income United Kingdom 210,605 - 210,605 Australia - 214,171 214,171 Total Government Support Income $ 210,605 $ 214,171 $ 424,776 Total Revenue and Government Support Income $ 3,322,386 $ 214,171 $ 3,536,557 Net Loss $ (2,992,228 ) $ (7,198,704 ) $ (10,190,932 ) IFPG BPT Total Year Ended June 30, 2023 IFPG BPT Total Revenue United Kingdom $ 1,061,191 $ - $ 1,061,191 Australia 6,491 - 6,491 Other 189,190 - 189,190 Total Revenue $ 1,256,872 $ - $ 1,256,872 Government Support Income United Kingdom 193,618 - 193,618 Australia - 544,010 544,010 Total Government Support Income $ 193,618 $ 544,010 $ 737,628 Total Revenue and Government Support Income $ 1,450,490 $ 544,010 $ 1,994,500 Net Loss $ (5,260,588 ) $ (5,403,967 ) $ (10,664,555 ) B) Long-lived assets and inventories IFPG BPT Total June 30, 2024 IFPG BPT Total Long-lived assets, net United Kingdom $ 4,626,798 $ - $ 4,626,798 Australia - 617,822 617,822 Total Long-Lived Assets $ 4,626,798 $ 617,822 $ 5,244,620 Inventories, net United Kingdom 731,813 - 731,813 Australia 45,724 - 45,724 Total Inventories $ 777,537 $ - $ 777,537 Total Long-Lived Assets and Inventories, net $ 5,404,335 $ 617,822 $ 6,022,157 IFPG BPT Total June 30, 2023 IFPG BPT Total Long-lived assets, net United Kingdom $ 5,730,831 $ - $ 5,730,831 Australia - 761,220 761,220 Total Long-Lived Assets $ 5,730,831 $ 761,220 $ 6,492,051 Inventories, net United Kingdom 880,696 - 880,696 Australia 99,211 - 99,211 Total Inventories $ 979,907 $ - $ 979,907 Total Long-Lived Assets and Inventories, net $ 6,710,738 $ 761,220 $ 7,471,958

INTELLIGENT FINGERPRINTING LI_2

INTELLIGENT FINGERPRINTING LIMITED ACQUISITION (Tables)	12 Months Ended
	Jun. 30, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
SCHEDULE OF FAIR VALUE OF THE CONSIDERATION TRANSFERRED IN THE ACQUISITION	The table below summarizes the fair value of the consideration transferred in the acquisition (pre-Company’s Reverse Stock Splits): SCHEDULE OF FAIR VALUE OF THE CONSIDERATION TRANSFERRED IN THE ACQUISITION Purchase consideration * Amount Cash $ 363,500 Note receivable settled for business acquisition 504,938 Common Stock - 2,963,091 0.5502 1,630,293 Series C Preferred Stock (base) - 2,363,003 0.5502 3,900,373 Series C Preferred Stock (holdback) - 500,000 0.5502 825,300 Purchase consideration of Common Stock and Series C Preferred Stock 825,300 Total purchase price $ 7,224,404 * The description of the IFP Acquisition below this table describes the purchase consideration on a post-Company’s Reverse Stock Splits basis.
SCHEDULE OF ASSETS ACQUIRED AND LIABILITIES ASSUMED, BASED ON THEIR RELATIVE FAIR VALUES	The final allocation of the purchase price of IFP to the assets acquired and liabilities assumed, based on their relative fair values, is as follows: SCHEDULE OF ASSETS ACQUIRED AND LIABILITIES ASSUMED, BASED ON THEIR RELATIVE FAIR VALUES Allocation of purchase consideration Amount Assets: Cash and cash equivalents $ 174,481 Inventory 774,625 Other current assets 345,038 Property and Equipment 52,170 Intangible assets 5,463,000 Goodwill 3,803,293 Total assets acquired 10,612,607 Liabilities: Accounts payable and accrued expenses (1,027,302 ) Notes payable (677,137 ) Convertible notes payable (1,683,764 ) Total liabilities assumed (3,388,203 ) Net assets $ 7,224,404
SCHEDULE OF UNAUDITED PRO-FORMA CONSOLIDATED RESULTS OF OPERATIONS	Unaudited pro-forma consolidated results of operations for the year ended June 30, 2024, is not required because the results of the acquired business are included in the Company’s results. The following unaudited pro-forma consolidated results of operations for the year ended June 30, 2023, has been prepared as if the acquisition of IFP had occurred on July 1, 2022 and includes adjustments for amortization related to the valuation of acquired intangibles: SCHEDULE OF UNAUDITED PRO-FORMA CONSOLIDATED RESULTS OF OPERATIONS Reported Pro forma Year Ended June 30, 2023 Reported Pro forma Revenue $ 1,256,872 $ 1,604,358 Net loss (10,664,555 ) (11,906,109 ) Net loss attributable to Intelligent Bio Solutions Inc. (10,631,720 ) (11,873,274 ) Net loss per share, basic and diluted (127.00 ) (141.84 )

INVENTORIES, NET (Tables)

INVENTORIES, NET (Tables)	12 Months Ended
	Jun. 30, 2024
Inventory Disclosure [Abstract]
SCHEDULE OF INVENTORIES	Inventories consist of the following: SCHEDULE OF INVENTORIES June 30, 2024 June 30, 2023 Raw material /Work-in-progress $ 188,693 $ 419,889 Finished goods 588,844 757,518 Less: provision for inventory obsolescence - (197,500 ) Inventories, net $ 777,537 $ 979,907

OTHER CURRENT ASSETS (Tables)

OTHER CURRENT ASSETS (Tables)	12 Months Ended
	Jun. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
SCHEDULE OF OTHER CURRENT ASSETS	Other current assets consist of the following: SCHEDULE OF OTHER CURRENT ASSETS June 30, 2024 June 30, 2023 Prepayments $ 363,071 $ 359,953 Goods and services tax receivable 17,011 20,418 Deposits 111,189 118,193 Deferred charges - 34,100 Other receivables 6,301 20,127 Total $ 497,572 $ 552,791

PROPERTY AND EQUIPMENT, NET (Ta

PROPERTY AND EQUIPMENT, NET (Tables)	12 Months Ended
	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT	Property and equipment consist of the following: SCHEDULE OF PROPERTY AND EQUIPMENT June 30, 2024 June 30, 2023 Production equipment $ 35,724 $ 30,348 Leasehold improvements 20,074 20,069 Other equipment 27,417 27,411 Construction in progress (CIP) 543,410 646,116 Gross property and equipment 626,625 723,944 Less: accumulated depreciation and amortization (60,775 ) (33,769 ) Property and equipment, net $ 565,850 $ 690,175
SUMMARY OF AMOUNT RECORDED IN THE CONSOLIDATED BALANCE SHEETS	The following table summarizes the amount of CIP recorded in property and equipment, net on the consolidated balance sheets: SUMMARY OF AMOUNT RECORDED IN THE CONSOLIDATED BALANCE SHEETS June 30, 2024 June 30, 2023 Investments in construction in progress $ 1,086,820 $ 1,292,232 Less: 50% contributed under government grant (543,410 ) (646,116 ) Carrying amount $ 543,410 $ 646,116

INTANGIBLE ASSETS, NET (Tables)

INTANGIBLE ASSETS, NET (Tables)	12 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
SCHEDULE OF OTHER INTANGIBLE ASSETS	Intangible assets, net consist of the following as June 30, 2024: SCHEDULE OF OTHER INTANGIBLE ASSETS Weighted Acquisition Effect of Accumulated Carrying Technology 7 years $ 5,119,000 $ 593,026 $ 1,559,822 $ 4,152,204 Customer relationships 3 years 252,000 29,194 164,030 117,164 Trade names and trademarks Indefinite 92,000 10,658 - 102,658 Total intangible assets $ 5,463,000 $ 632,878 $ 1,723,852 $ 4,372,026 Intangible assets, net consist of the following as of June 30, 2023: Weighted Acquisition Effect of Accumulated Carrying Technology 7 years $ 5,119,000 $ 603,422 $ 780,500 $ 4,941,922 Customer relationships 3 years 252,000 29,127 70,282 210,845 Trade names and trademarks Indefinite 92,000 10,634 - 102,634 Total intangible assets $ 5,463,000 $ 643,183 $ 850,782 $ 5,255,401
SCHEDULE OF EXPECTED AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS	Amortization expense for the intangible assets is expected to be as follows over the next five years, and thereafter: SCHEDULE OF EXPECTED AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS 2025 $ 884,627 2026 814,329 2027 790,896 2028 790,896 2029 790,896 Thereafter 197,724 Total $ 4,269,368

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	12 Months Ended
	Jun. 30, 2024
Payables and Accruals [Abstract]
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES	Accounts payable and accrued expenses consist of the following: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES June 30, 2024 June 30, 2023 Accounts and other payables $ 602,337 $ 1,196,222 Accruals 607,176 777,086 Deferred consideration * - 208,500 Goods and services tax payable 50,283 - Accrued compensation and related payables 444,772 428,220 Total $ 1,704,568 $ 2,610,028 * Deferred consideration relates to the fair value of $ 208,500 500,000 500,000 6,248

LEASES (Tables)

LEASES (Tables)	12 Months Ended
	Jun. 30, 2024
Leases [Abstract]
SCHEDULE OF LEASE EXPENSES	The components of operating lease expense are as follows: SCHEDULE OF LEASE EXPENSES 2024 2023 Year Ended June 30, 2024 2023 Amortization of operating lease right-of-use assets $ 238,730 $ 152,251 Interest on operating lease liabilities 71,667 68,357 Total operating lease costs $ 310,397 $ 220,608
SCHEDULE OF MATURITIES OF OPERATING LEASES TO OPERATING LEASE LIABILITIES	The reconciliation of the maturities of the operating leases to the operating lease liabilities recorded in the consolidated balance sheet as of June 30, 2024, is as follows: SCHEDULE OF MATURITIES OF OPERATING LEASES TO OPERATING LEASE LIABILITIES 2025 $ 308,770 2026 83,509 Total lease payments 392,279 Less: imputed interest (36,121 ) Present value of lease liabilities $ 356,158

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
SCHEDULE OF CLOSING HOLDBACK SHARES OF SERIES C PREFERRED STOCK AT FAIR VALUE ON RECURRING	The following table provides a reconciliation of the beginning and ending balance of the Closing Holdback Shares (in the form of Series C Preferred Stock) measured at fair value on a recurring basis during the period: SCHEDULE OF CLOSING HOLDBACK SHARES OF SERIES C PREFERRED STOCK AT FAIR VALUE ON RECURRING Preferred stock Balance at June 30, 2022 $ - Fair value of holdback Series C Preferred Stock at acquisition (Note 5) 825,300 Fair value gain on revaluation of holdback Series C Preferred Stock (616,800 ) Balance at June 30, 2023 208,500 Fair value gain on revaluation of holdback Series C Preferred Stock (175,738 ) Conversion of Series C Preferred Stock into Common Stock (32,762 ) Balance at June 30, 2024 $ -

INCOME TAX (Tables)

INCOME TAX (Tables)	12 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES	The components of net deferred taxes are as follows: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES June 30, 2024 June 30, 2023 Deferred tax assets (liabilities): Net operating loss - U.S. $ $ 3,914,445 Net operating loss - Foreign 6,090,380 5,347,487 Employee benefits 118,132 153,199 Inventory adjustments (1,124 ) 38,034 Foreign exchange 31,902 77,539 Total deferred tax assets, net 10,421,568 9,530,704 Less: valuation allowance (10,421,568 ) (9,530,704 ) Net deferred taxes $ — $ —
SCHEDULE OF PROVISION FOR INCOME TAXES	Our statutory income tax rate is expected to be approximately 21%. The provision for income taxes consisted of the following: SCHEDULE OF PROVISION FOR INCOME TAXES 2024 2023 Year Ended June 30, 2024 2023 Current $ — $ — Deferred — — Total $ — $ —
SCHEDULE OF RECONCILIATION OF INCOME TAX EXPENSE (BENEFIT)	The reconciliation between the income tax expense (benefit) calculated by applying statutory rates to net loss and the income tax expense reported in the accompanying consolidated financial statements is as follows: SCHEDULE OF RECONCILIATION OF INCOME TAX EXPENSE (BENEFIT) 2024 2023 Year Ended June 30, 2024 2023 U.S. federal statutory rate applies to pretax income (loss) $ (1,848,116 ) $ (2,310,635 ) Different tax rate of subsidiary (99,401 ) (18,715 ) Permanent differences 246,168 680,221 Tax benefit on carry forward losses of acquired business - (3,289,886 ) Cumulative adjustment to deferred taxes 797,234 1,681,562 Change in state tax rates and other 13,250 (209,226 ) Change in valuation allowance 890,865 3,466,679 Total income tax provision (benefit) $ — $ —

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	12 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
SCHEDULE OF BASIC LOSS PER COMMON SHARE POTENTIAL DILUTIVE SECURITIES	SCHEDULE OF BASIC LOSS PER COMMON SHARE POTENTIAL DILUTIVE SECURITIES Years Ended June 30, 2024 2023 Net loss attributable to Intelligent Bio Solutions Inc. $ (10,156,759 ) $ (10,631,720 ) Basic and diluted net loss per share attributed to common shareholders $ (6.38 ) $ (127.00 ) Weighted-average number of shares outstanding 1,592,746 83,717
SCHEDULE OF ANTI-DILUTIVE WARRANTS	The following outstanding warrants, options and preferred shares were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Post-Consolidated Company Reverse Stock Split: Anti-dilutive warrants SCHEDULE OF ANTI-DILUTIVE WARRANTS 2024 2023 Year Ended June 30, 2024 2023 Warrants 6,310,684 35,547 Anti-dilutive 6,310,684 35,547

ORGANIZATION AND DESCRIPTION _2

ORGANIZATION AND DESCRIPTION OF THE BUSINESS (Details Narrative)	Jan. 26, 2024	Feb. 09, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Reverse stock split	1-for-12	1-for-20
February 2023 Reverse Stock Split [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Reverse stock split		1-for-20

LIQUIDITY AND GOING CONCERN (De

LIQUIDITY AND GOING CONCERN (Details Narrative) - USD ($)					12 Months Ended
		Mar. 12, 2024	Feb. 07, 2024	Oct. 04, 2023	Jun. 30, 2024		Jun. 30, 2023		Jun. 30, 2022	[3]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Proceeds from issuance of preferred stocks and warrants		$ 10,100,000	$ 1,770,000	$ 4,380,000
Sale of stock, consideration received net of transaction costs		$ 9,120,000	$ 1,580,000	$ 3,790,000
Net loss	[1]				$ 10,156,759		$ 10,631,720
Shareholders' equity					8,183,191	[2]	3,686,998	[2]	$ 6,545,771
Working capital					3,080,000
Accumulated deficit	[2]				51,964,332		41,807,573
Cash and cash equivalents	[2]				$ 6,304,098		$ 1,537,244
[1]Common Stock and per share amounts have been retroactively adjusted to reflect the decreased number of shares resulting from the[2]Common Stock has been retroactively adjusted to reflect the decreased number of shares resulting from the[3]Common Stock has been retroactively adjusted to reflect the decreased number of shares resulting from the

SCHEDULE OF REVENUE SALES OF RE

SCHEDULE OF REVENUE SALES OF READERS CARTRIDGES AND OTHER SALES WHICH REPRESENTS ACCESSORIES (Details) - USD ($)		12 Months Ended
		Jun. 30, 2024	Jun. 30, 2023
Product Information [Line Items]
Total revenue	[1]	$ 3,111,781	$ 1,256,872
Sales of Goods - Cartidges [Member]
Product Information [Line Items]
Total revenue		1,549,409	724,304
Sales of Goods - Readers [Member]
Product Information [Line Items]
Total revenue		938,897	335,863
Other Sales [Member]
Product Information [Line Items]
Total revenue		$ 623,475	$ 196,705
[1]Common Stock and per share amounts have been retroactively adjusted to reflect the decreased number of shares resulting from the

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)		12 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Apr. 16, 2024	Jun. 30, 2021
Property, Plant and Equipment [Line Items]
Foreign currency translation gain (loss)		$ 137,118	$ 212,639
Cash equivalents		0	0
Cash FDIC insured amount		5,781,130	1,114,687
Goodwill, Impairment Loss	[1]		4,158,670
Deferred grant income					$ 4,700,000
Construction in progress		543,410	646,116
Project cost				$ 1,650,000
Research and development tax refund		$ 424,776	609,684
Grant Income [Member]
Property, Plant and Equipment [Line Items]
Other Income			$ 127,944
Other Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life		3 years
Production Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life		2 years
Production Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life		4 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]		Useful Life, Lease Term [Member]
[1]Common Stock and per share amounts have been retroactively adjusted to reflect the decreased number of shares resulting from the

SCHEDULE OF REVENUE, GOVERNMENT

SCHEDULE OF REVENUE, GOVERNMENT SUPPORT INCOME, NET LOSS AND LONG LIVED ASSETS AND INVENTORIES (Details) - USD ($)		12 Months Ended
		Jun. 30, 2024	Jun. 30, 2023
Revenue from External Customer [Line Items]
Total Revenue	[1]	$ 3,111,781	$ 1,256,872
Total Government Support Income	[1]	424,776	737,628
Total Revenue and Government Support Income		3,536,557	1,994,500
Net Loss	[1],[2]	(10,190,932)	(10,664,555)
Total Long-Lived Assets		5,244,620	6,492,051
Total Inventories	[3]	777,537	979,907
Total Long-Lived Assets and Inventories, net		6,022,157	7,471,958
UNITED KINGDOM
Revenue from External Customer [Line Items]
Total Revenue		2,597,264	1,061,191
Total Government Support Income		210,605	193,618
Total Long-Lived Assets		4,626,798	5,730,831
Total Inventories		731,813	880,696
AUSTRALIA
Revenue from External Customer [Line Items]
Total Revenue		43,955	6,491
Total Government Support Income		214,171	544,010
Total Long-Lived Assets		617,822	761,220
Total Inventories		45,724	99,211
Other Country [Member]
Revenue from External Customer [Line Items]
Total Revenue		470,562	189,190
IFPG [Member]
Revenue from External Customer [Line Items]
Total Revenue		3,111,781	1,256,872
Total Government Support Income		210,605	193,618
Total Revenue and Government Support Income		3,322,386	1,450,490
Net Loss		(2,992,228)	(5,260,588)
Total Long-Lived Assets		4,626,798	5,730,831
Total Inventories		777,537	979,907
Total Long-Lived Assets and Inventories, net		5,404,335	6,710,738
IFPG [Member] | UNITED KINGDOM
Revenue from External Customer [Line Items]
Total Revenue		2,597,264	1,061,191
Total Government Support Income		210,605	193,618
Total Long-Lived Assets		4,626,798	5,730,831
Total Inventories		731,813	880,696
IFPG [Member] | AUSTRALIA
Revenue from External Customer [Line Items]
Total Revenue		43,955	6,491
Total Government Support Income
Total Long-Lived Assets
Total Inventories		45,724	99,211
IFPG [Member] | Other Country [Member]
Revenue from External Customer [Line Items]
Total Revenue		470,562	189,190
Biosensor Platform Technology [Member]
Revenue from External Customer [Line Items]
Total Revenue
Total Government Support Income		214,171	544,010
Total Revenue and Government Support Income		214,171	544,010
Net Loss		(7,198,704)	(5,403,967)
Total Long-Lived Assets		617,822	761,220
Total Inventories
Total Long-Lived Assets and Inventories, net		617,822	761,220
Biosensor Platform Technology [Member] | UNITED KINGDOM
Revenue from External Customer [Line Items]
Total Revenue
Total Government Support Income
Total Long-Lived Assets
Total Inventories
Biosensor Platform Technology [Member] | AUSTRALIA
Revenue from External Customer [Line Items]
Total Revenue
Total Government Support Income		214,171	544,010
Total Long-Lived Assets		617,822	761,220
Total Inventories
Biosensor Platform Technology [Member] | Other Country [Member]
Revenue from External Customer [Line Items]
Total Revenue
[1]Common Stock and per share amounts have been retroactively adjusted to reflect the decreased number of shares resulting from the[2]Common Stock has been retroactively adjusted to reflect the decreased number of shares resulting from the[3]Common Stock has been retroactively adjusted to reflect the decreased number of shares resulting from the

SCHEDULE OF FAIR VALUE OF THE C

SCHEDULE OF FAIR VALUE OF THE CONSIDERATION TRANSFERRED IN THE ACQUISITION (Details) - USD ($)			12 Months Ended
		Oct. 04, 2022	Jun. 30, 2024	Jun. 30, 2023
Business Acquisition [Line Items]
Cash				$ 363,500
Note receivable settled for business acquisition				$ 504,938
Intelligent Fingerprinting Limited [Member]
Business Acquisition [Line Items]
Cash		$ 363,500
Note receivable settled for business acquisition		504,938
Total purchase price	[1]	7,224,404
Intelligent Fingerprinting Limited [Member] | Series C Preferred Stock Base [Member]
Business Acquisition [Line Items]
Purchase consideration of Common Stock and Series C Preferred Stock		3,900,373
Intelligent Fingerprinting Limited [Member] | Series C Preferred Stock Holdback [Member]
Business Acquisition [Line Items]
Purchase consideration of Common Stock and Series C Preferred Stock		825,300
Intelligent Fingerprinting Limited [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Purchase consideration of Common Stock and Series C Preferred Stock		$ 1,630,293
[1]The description of the IFP Acquisition below this table describes the purchase consideration on a post-Company’s Reverse Stock Splits basis.

SCHEDULE OF FAIR VALUE OF THE_2

SCHEDULE OF FAIR VALUE OF THE CONSIDERATION TRANSFERRED IN THE ACQUISITION (Details)(Parenthetical) - Intelligent Fingerprinting Limited [Member]	Oct. 04, 2022 $ / shares shares
Series C Preferred Stock Holdback [Member]
Business Acquisition [Line Items]
Stock issued in acquisition | shares	500,000
Share price | $ / shares	$ 0.5502
Common Stock [Member]
Business Acquisition [Line Items]
Stock issued in acquisition | shares	2,963,091
Share price | $ / shares	$ 0.5502
Series C Preferred Stock Base [Member]
Business Acquisition [Line Items]
Stock issued in acquisition | shares	2,363,003
Share price | $ / shares	$ 0.5502

SCHEDULE OF ASSETS ACQUIRED AND

SCHEDULE OF ASSETS ACQUIRED AND LIABILITIES ASSUMED, BASED ON THEIR RELATIVE FAIR VALUES (Details) - Intelligent Fingerprinting Limited [Member]	Oct. 04, 2022 USD ($)
Business Acquisition [Line Items]
Cash and cash equivalents	$ 174,481
Inventory	774,625
Other current assets	345,038
Property and Equipment	52,170
Intangible assets	5,463,000
Goodwill	3,803,293
Total assets acquired	10,612,607
Accounts payable and accrued expenses	(1,027,302)
Notes payable	(677,137)
Convertible notes payable	(1,683,764)
Total liabilities assumed	(3,388,203)
Net assets	$ 7,224,404	[1]
[1]The description of the IFP Acquisition below this table describes the purchase consideration on a post-Company’s Reverse Stock Splits basis.

SCHEDULE OF UNAUDITED PRO-FORMA

SCHEDULE OF UNAUDITED PRO-FORMA CONSOLIDATED RESULTS OF OPERATIONS (Details)	12 Months Ended
	Jun. 30, 2023 USD ($) $ / shares
Revenue	$ 1,256,872
Net loss	(10,664,555)
Net loss attributable to Intelligent Bio Solutions Inc.	$ (10,631,720)
Net loss per share, basic | $ / shares	$ (127)
Net loss per share, diluted | $ / shares	$ (127)
Pro Forma [Member]
Revenue	$ 1,604,358
Net loss	(11,906,109)
Net loss attributable to Intelligent Bio Solutions Inc.	$ (11,873,274)
Net loss per share, basic | $ / shares	$ (141.84)
Net loss per share, diluted | $ / shares	$ (141.84)

INTELLIGENT FINGERPRINTING LI_3

INTELLIGENT FINGERPRINTING LIMITED ACQUISITION (Details Narrative)

3 Months Ended

12 Months Ended

May 10, 2023 shares

May 08, 2023 shares

Oct. 04, 2022 USD ($) $ / shares shares

Dec. 31, 2023 shares

Jun. 30, 2024 USD ($) shares

Jun. 30, 2023 USD ($) shares

Oct. 04, 2023

Feb. 09, 2023

Oct. 04, 2022 GBP (£) shares

Jun. 30, 2022 shares

Jun. 16, 2022 USD ($)

Business Acquisition [Line Items]

Equity issuance costs | $

$ 518,914

Conversion of Stock, Shares Issued

500,000

Series C Preferred Stock [Member]

Business Acquisition [Line Items]

Reserved for future issuance

1,649,273

1,649,273

Conversion ratio

0.15

0.0125

Shares, Outstanding

3,512,277

Series C Preferred Stock [Member] | Share Exchange Agreement [Member]

Business Acquisition [Line Items]

Stock issued during period shares acquisitions

500,000

Conversion ratio

0.0125

0.0125

Series C Preferred Stock [Member] | Share Exchange Agreement [Member] | IFP Lenders [Member]

Business Acquisition [Line Items]

Stock issued during period shares new issues

1,149,273

Hold-back Series C Preferred Stock [Member] | Share Exchange Agreement [Member]

Business Acquisition [Line Items]

Stock issued during period shares acquisitions

500,000

Common Stock [Member]

Business Acquisition [Line Items]

Stock issued during period shares acquisitions

[1]

12,347

Shares, Outstanding

[1]

3,456,000

194,200

62,042

Conversion of Stock, Shares Issued

43,902

5,728,723

Lender Preferred Shares [Member] | Series C Preferred Stock [Member]

Business Acquisition [Line Items]

Shares, Outstanding

1,149,273

Closing Holdback Shares [Member] | Series C Preferred Stock [Member]

Business Acquisition [Line Items]

Shares, Outstanding

500,000

500,000

Conversion of Stock, Shares Issued

6,248

Shares, Issued

500,000

Intelligent Fingerprinting Limited [Member]

Business Acquisition [Line Items]

Acquisition percentage

100%

100%

Loan receivable | $

$ 504,938

$ 504,938

Acquired intangible assets | $

5,463,000

Intelligent Fingerprinting Limited [Member] | Technology-Based Intangible Assets [Member]

Business Acquisition [Line Items]

Acquired intangible assets | $

$ 5,119,000

Estimated useful life

7 years

Intelligent Fingerprinting Limited [Member] | Customer Relationships [Member]

Business Acquisition [Line Items]

Acquired intangible assets | $

$ 252,000

Estimated useful life

3 years

Intelligent Fingerprinting Limited [Member] | Trademarks and Trade Names [Member]

Business Acquisition [Line Items]

Acquired intangible assets | $

$ 92,000

Intelligent Fingerprinting Limited [Member] | Various Loan Agreement [Member]

Business Acquisition [Line Items]

Accrued liabilities

$ 1,425,307

£ 1,254,270

Loan interest percentage

17%

17%

Loan variable interest percentage

22%

22%

Intelligent Fingerprinting Limited [Member] | Series C Convertible Preferred Stock [Member]

Business Acquisition [Line Items]

Business Acquisition, Equity Interest Issued or Issuable, Number of Shares

2,363,003

Intelligent Fingerprinting Limited [Member] | Series C Preferred Stock [Member]

Business Acquisition [Line Items]

Equity issuance costs | $

$ 806,397

Intelligent Fingerprinting Limited [Member] | Common Stock [Member]

Business Acquisition [Line Items]

Business Acquisition, Equity Interest Issued or Issuable, Number of Shares

2,963,091

Intelligent Fingerprinting Limited [Member] | Common Stock [Member] | February 2023 Reverse Stock Split [Member]

Business Acquisition [Line Items]

Business Acquisition, Equity Interest Issued or Issuable, Number of Shares

12,347

Share Exchange Agreement [Member] | Series C Convertible Preferred Stock [Member]

Business Acquisition [Line Items]

Preferred Stock, Par or Stated Value Per Share | $ / shares

$ 0.01

[1]Common Stock has been retroactively adjusted to reflect the decreased number of shares resulting from the

SCHEDULE OF INVENTORIES (Detail

SCHEDULE OF INVENTORIES (Details) - USD ($)		Jun. 30, 2024	Jun. 30, 2023
Inventory Disclosure [Abstract]
Raw material /Work-in-progress		$ 188,693	$ 419,889
Finished goods		588,844	757,518
Less: provision for inventory obsolescence			(197,500)
Inventories, net	[1]	$ 777,537	$ 979,907
[1]Common Stock has been retroactively adjusted to reflect the decreased number of shares resulting from the

SCHEDULE OF OTHER CURRENT ASSET

SCHEDULE OF OTHER CURRENT ASSETS (Details) - USD ($)		Jun. 30, 2024	Jun. 30, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepayments		$ 363,071	$ 359,953
Goods and services tax receivable		17,011	20,418
Deposits		111,189	118,193
Deferred charges			34,100
Other receivables		6,301	20,127
Total	[1]	$ 497,572	$ 552,791
[1]Common Stock has been retroactively adjusted to reflect the decreased number of shares resulting from the

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)		Jun. 30, 2024	Jun. 30, 2023
Property, Plant and Equipment [Line Items]
Gross property and equipment		$ 626,625	$ 723,944
Less: accumulated depreciation and amortization		(60,775)	(33,769)
Property and equipment, net	[1]	565,850	690,175
Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment		35,724	30,348
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment		20,074	20,069
Other Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment		27,417	27,411
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment		$ 543,410	$ 646,116
[1]Common Stock has been retroactively adjusted to reflect the decreased number of shares resulting from the

SUMMARY OF AMOUNT RECORDED IN T

SUMMARY OF AMOUNT RECORDED IN THE CONSOLIDATED BALANCE SHEETS (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Investments in construction in progress	$ 1,086,820	$ 1,292,232
Less: 50% contributed under government grant	(543,410)	(646,116)
Carrying amount	$ 543,410	$ 646,116

PROPERTY AND EQUIPMENT, NET (De

PROPERTY AND EQUIPMENT, NET (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Depreciation of property and equipment	$ 15,108	$ 33,769
Construction of building		$ 509,416
Percentage of reimbursement on construction cost	50%

SCHEDULE OF OTHER INTANGIBLE AS

SCHEDULE OF OTHER INTANGIBLE ASSETS (Details) - USD ($)		12 Months Ended
		Jun. 30, 2024	Jun. 30, 2023
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Acquisition cost		$ 5,463,000	$ 5,463,000
Intangible assets, Effect of foreign currency		632,878	643,183
Intangible assets, Accumulated amortization		1,723,852	850,782
Intangible assets, Carrying value	[1]	$ 4,372,026	$ 5,255,401
Technology-Based Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted average useful lives (years)		7 years	7 years
Intangible assets, Acquisition cost		$ 5,119,000	$ 5,119,000
Intangible assets, Effect of foreign currency		593,026	603,422
Intangible assets, Accumulated amortization		1,559,822	780,500
Intangible assets, Carrying value		$ 4,152,204	$ 4,941,922
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted average useful lives (years)		3 years	3 years
Intangible assets, Acquisition cost		$ 252,000	$ 252,000
Intangible assets, Effect of foreign currency		29,194	29,127
Intangible assets, Accumulated amortization		164,030	70,282
Intangible assets, Carrying value		117,164	210,845
Trademarks and Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Acquisition cost		92,000	92,000
Intangible assets, Effect of foreign currency		10,658	10,634
Intangible assets, Accumulated amortization
Intangible assets, Carrying value		$ 102,658	$ 102,634
Weighted average useful lives (years)		Indefinite	Indefinite
[1]Common Stock has been retroactively adjusted to reflect the decreased number of shares resulting from the

SCHEDULE OF EXPECTED AMORTIZATI

SCHEDULE OF EXPECTED AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS (Details)	Jun. 30, 2024 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2025	$ 884,627
2026	814,329
2027	790,896
2028	790,896
2029	790,896
Thereafter	197,724
Total	$ 4,269,368

INTANGIBLE ASSETS, NET (Details

INTANGIBLE ASSETS, NET (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible assets, Accumulated amortization	$ 1,723,852	$ 850,782
Amortization of intangible assets	$ 947,436	$ 805,764

SCHEDULE OF ACCOUNTS PAYABLE AN

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($)		12 Months Ended
		Jun. 30, 2024	Jun. 30, 2023
Payables and Accruals [Abstract]
Accounts and other payables		$ 602,337	$ 1,196,222
Accruals		607,176	777,086
Deferred consideration	[1]		208,500
Goods and services tax payable		50,283
Accrued compensation and related payables		444,772	428,220
Total	[2]	$ 1,704,568	$ 2,610,028
Conversion of stock shares		500,000
Conversion of stock shares		6,248
[1]Deferred consideration relates to the fair value of $ 208,500 500,000 500,000 6,248

SCHEDULE OF ACCOUNTS PAYABLE _2

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) (Parenthetical) - Intelligent Fingerprinting Limited [Member] - Second Installment [Member]	12 Months Ended
	Jun. 30, 2024 USD ($) shares
Restructuring Cost and Reserve [Line Items]
Fair value of held-back shares | $	$ 208,500
No. of held back Series C Preferred Stock | shares	500,000

NOTE PAYABLE (Details Narrative

NOTE PAYABLE (Details Narrative)	12 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Interest rate, debt	0.97%
Gross revenue, rate	10%
Sales to distributor, rate	50%

SCHEDULE OF LEASE EXPENSES (Det

SCHEDULE OF LEASE EXPENSES (Details) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Leases [Abstract]
Amortization of operating lease right-of-use assets	$ 238,730	$ 152,251
Interest on operating lease liabilities	71,667	68,357
Total operating lease costs	$ 310,397	$ 220,608

SCHEDULE OF MATURITIES OF OPERA

SCHEDULE OF MATURITIES OF OPERATING LEASES TO OPERATING LEASE LIABILITIES (Details)	Jun. 30, 2024 USD ($)
Leases [Abstract]
2025	$ 308,770
2026	83,509
Total lease payments	392,279
Less: imputed interest	(36,121)
Present value of lease liabilities	$ 356,158

LEASES (Details Narrative)

LEASES (Details Narrative)	Jun. 30, 2024	Jun. 30, 2023
Leases [Abstract]
Weighted average remaining lease-term	1 year 3 months 18 days	2 years 3 months 18 days
Weighted average, discount rate	13.20%	13.20%

SHAREHOLDERS_ EQUITY (Details N

SHAREHOLDERS’ EQUITY (Details Narrative)

3 Months Ended

12 Months Ended

Mar. 12, 2024 USD ($)

Mar. 08, 2024 USD ($) $ / shares shares

Feb. 29, 2024 USD ($) shares

Feb. 07, 2024 USD ($)

Feb. 04, 2024 USD ($) $ / shares shares

Jan. 26, 2024

Oct. 04, 2023 USD ($) $ / shares shares

May 10, 2023 shares

Feb. 09, 2023

Dec. 31, 2023 shares

Jun. 30, 2024 USD ($) $ / shares shares

Jun. 30, 2023 USD ($) shares

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants to purchase common stock

6,310,684

Common Stock, Shares, Issued

3,456,000

194,200

Sale of stock, consideration received net of transaction costs | $

$ 9,120,000

$ 1,580,000

$ 3,790,000

Stockholders equity, reverse stock split

1-for-12

1-for-20

Underwriters warrants to purchase percentage

5%

Number of shares converted

6,248

Number of shares issued

500,000

Expense related agreement | $

$ 230,496

$ 260,000

Board of Directors Chairman [Member] | 2019 Stock Incentive Plan [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Shares issuance

133,333

Employees [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Expense related agreement | $

$ 19,578

Shares granted

5,762

Weighted average grant date fair value | $ / shares

$ 3.40

IFP Sellers [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Post company reverse stock splits

6,248

Closing holdback shares

74,971

Series E Warrants [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants exercise price, per share | $ / shares

$ 0.55

Reverse stock split per share | $ / shares

$ 6.60

Series E Convertible Preferred Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares converted

5,728,723

Series F Warrants [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Post company reverse stock splits

612,182

Issuance of common stock upon cashless exercise of warrants, shares

7,346,178

Series C Preferred Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Preferred stock convertible conversion ratio

0.15

0.0125

Reverse stock split convertible conversion ratio

0.0125

Series C Preferred Stock [Member] | IFP Sellers [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Closing holdback shares

500,000

January 2024 Reverse Stock Split [Member] | Series E Warrants [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants exercise price, per share | $ / shares

$ 2.9232

Stockholders equity, reverse stock split

(i) the then exercise price and (ii) 90% of the five-day volume weighted average price for the five trading days immediately following the date the Company effects a reverse stock split. As a result of the January 2024 Reverse Stock Split, the exercise price of the Series E Warrants was reset to $2.9232 per share. The original exercise price of the Series F Warrants was $0.55 per share ($6.60 post-Company’s Reverse Stock Splits) but is subject to an alternate cashless exercise option pursuant to which the holder has the right to receive an aggregate number of shares of common stock on a one-for-one basis (one-for-1/12 post-Company’s Reverse Stock Splits) (subject to adjustment)

January 2024 Reverse Stock Split [Member] | Series F Warrants [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants exercise price, per share | $ / shares

$ 0.55

Reverse stock split per share | $ / shares

6.60

Securities Purchase Agreement [Member] | March 2024 Private Placement [Member] | Series H-2 Warrants [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants expiration term

5 years

Securities Purchase Agreement [Member] | March 2024 Private Placement [Member] | Series H-1 and H-2 Warrants [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Series H-1 and H-2 warrants exercised | $ / shares

$ 4.55

October 2023 Offering [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Series H-1 and H-2 warrants exercised | $ / shares

$ 0.55

Common Stock, Shares, Issued

2,232,221

Post company reverse stock splits

186,018

Proceeds from Issuance or Sale of Equity | $

$ 4,380,000

Sale of stock, consideration received net of transaction costs | $

$ 3,790,000

October 2023 Offering [Member] | Series E Warrants [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants expiration term

5 years 6 months

October 2023 Offering [Member] | Series E Convertible Preferred Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Preferred Stock, Shares Issued

5,728,723

October 2023 Offering [Member] | Series E Preferred Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Post company reverse stock splits

663,412

Number of warrants, shares

7,960,944

October 2023 Offering [Member] | Series F Warrants [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Post company reverse stock splits

663,412

Number of warrants, shares

7,960,944

October 2023 Offering [Member] | March 2024 Private Placement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Proceeds from offering | $

$ 10,100,000

Placement Agency Agreement [Member] | March 2024 Private Placement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Sale of stock description of transaction

(i) a cash fee equal to 8.0% of the gross proceeds received by the Company in the March 2024 Offering, (ii) a management fee equal to 1.0% of the gross proceeds received by the Company in the March 2024 Offering, (iii) common stock purchase warrants to purchase such number of shares of common stock equal to 5% of the aggregate number Shares and Pre-Funded Warrants sold in the March 2024 Offering, which warrants are to have an exercise price equal to 125% of the offering price per share and an expiration date of 5 years from issuance (the “Placement Agent Warrants”); (iv) a cash fee equal to 9.0% of the gross proceeds received by the Company from the cash exercise of any H-1 Warrants and H-2 Warrants; and (vi) reimbursement of the Agent’s expenses in an amount up to $145,000.

Cash fee | $

$ 145,000

Warrant Inducement Agreements [Member] | Series E Warrants [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants exercise price, per share | $ / shares

$ 2.9232

Proceeds from issuance of warrants | $

$ 1,770,000

Warrant Inducement Agreements [Member] | Series G Warrants [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Series G warrrants exercise price | $ / shares

$ 4.50

Warrants expiration term

5 years 6 months

Consulting Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Cash fee | $

$ 25,000

Restricted shares of common stock

37,500

Expense related agreement | $

$ 179,625

Advisory Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Cash fee | $

$ 5,000

Restricted shares of common stock

5,260

Grant of restricted common stock | $

$ 4,000

12,000

Clear Think Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Expense related agreement | $

$ 25,195

Common Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants exercise price, per share | $ / shares

$ 0.6875

Post company reverse stock splits

33,171

477,394

Reverse stock split per share | $ / shares

$ 8.25

Public offering shares

398,047

Closing holdback shares

[1]

12,347

Number of shares issued

43,902

5,728,723

Issuance of common stock upon cashless exercise of warrants, shares

[1]

655,086

16,099

Common Stock [Member] | Securities Purchase Agreement [Member] | March 2024 Private Placement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Shares issuance

675,183

Series G warrrants exercise price | $ / shares

$ 0.01

Common Stock [Member] | Warrant Inducement Agreements [Member] | Series E Warrants [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Shares, issued

606,064

Warrant [Member] | Securities Purchase Agreement [Member] | March 2024 Private Placement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Shares issuance

1,548,150

Warrant [Member] | Securities Purchase Agreement [Member] | March 2024 Private Placement [Member] | Series H-1 Warrants [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Shares issuance

2,223,333

Warrant [Member] | Securities Purchase Agreement [Member] | March 2024 Private Placement [Member] | Series H-2 Warrants [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Shares issuance

2,223,333

[1]Common Stock has been retroactively adjusted to reflect the decreased number of shares resulting from the

SCHEDULE OF CLOSING HOLDBACK SH

SCHEDULE OF CLOSING HOLDBACK SHARES OF SERIES C PREFERRED STOCK AT FAIR VALUE ON RECURRING (Details) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value gain on revaluation of holdback Series C Preferred Stock	$ (175,738)	$ (616,800)
Conversion of Series C Preferred Stock into Common Stock	57,287	36,888
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Preferred Stock carried at fair value, beginning value	208,500
Fair value of holdback Series C Preferred Stock at acquisition		825,300
Fair value gain on revaluation of holdback Series C Preferred Stock	(175,738)	(616,800)
Conversion of Series C Preferred Stock into Common Stock	(32,762)
Preferred Stock carried at fair value, ending value		$ 208,500

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details Narrative)	12 Months Ended
	Jun. 30, 2024 shares	Oct. 04, 2023	Feb. 09, 2023	Oct. 04, 2022
Conversion of stock shares	500,000
Conversion of stock shares	6,248
Series C Preferred Stock [Member]
Preferred stock convertible conversion ratio		0.15	0.0125
Series C Preferred Stock [Member] | Share Exchange Agreement [Member]
Closing holdback shares	500,000
Preferred stock convertible conversion ratio				0.0125
Series C Preferred Stock [Member] | Share Exchange Agreement [Member] | January 2024 Reverse Stock Split [Member]
Preferred stock convertible conversion ratio	0.0125

RELATED-PARTY TRANSACTIONS (Det

RELATED-PARTY TRANSACTIONS (Details Narrative) - October 2023 Offering [Member] - $ / shares	12 Months Ended
	Jun. 30, 2024	Oct. 04, 2023
Related Party Transaction [Line Items]
Public offering price		$ 0.55
Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Stock purchased, shares	112,727
Public offering price	$ 0.55
Christopher Towers [Member]
Related Party Transaction [Line Items]
Stock purchased, shares	9,090

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - Cliantha Research [Member] - USD ($)	Feb. 09, 2024	Jun. 30, 2024
Payment for milestone	$ 494,197
Remaining milestone payments		$ 197,679

SCHEDULE OF DEFERRED TAX ASSETS

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Net operating loss - U.S.	$ 4,182,278	$ 3,914,445
Net operating loss - Foreign	6,090,380	5,347,487
Employee benefits	118,132	153,199
Inventory adjustments	(1,124)	38,034
Foreign exchange	31,902	77,539
Total deferred tax assets, net	10,421,568	9,530,704
Less: valuation allowance	(10,421,568)	(9,530,704)
Net deferred taxes

SCHEDULE OF PROVISION FOR INCOM

SCHEDULE OF PROVISION FOR INCOME TAXES (Details) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Current
Deferred
Total

SCHEDULE OF RECONCILIATION OF I

SCHEDULE OF RECONCILIATION OF INCOME TAX EXPENSE (BENEFIT) (Details) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Income Tax Disclosure [Abstract]
U.S. federal statutory rate applies to pretax income (loss)	$ (1,848,116)	$ (2,310,635)
Different tax rate of subsidiary	(99,401)	(18,715)
Permanent differences	246,168	680,221
Tax benefit on carry forward losses of acquired business		(3,289,886)
Cumulative adjustment to deferred taxes	797,234	1,681,562
Change in state tax rates and other	13,250	(209,226)
Change in valuation allowance	890,865	3,466,679
Total

INCOME TAX (Details Narrative)

INCOME TAX (Details Narrative) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Deferred Tax Assets, Valuation Allowance	$ 10,421,568	$ 9,530,704
Operating Loss Carryforwards	$ 49,097,053	$ 44,492,527

SCHEDULE OF BASIC LOSS PER COMM

SCHEDULE OF BASIC LOSS PER COMMON SHARE POTENTIAL DILUTIVE SECURITIES (Details) - USD ($)		12 Months Ended
		Jun. 30, 2024	Jun. 30, 2023
Earnings Per Share [Abstract]
Net loss attributable to Intelligent Bio Solutions Inc.	[1]	$ (10,156,759)	$ (10,631,720)
Basic net loss per share attributed to common shareholders	[1]	$ (6.38)	$ (127)
Diluted net loss per share attributed to common shareholders	[1]	$ (6.38)	$ (127)
Weighted-average number of shares outstanding, basic	[1]	1,592,746	83,717
Weighted-average number of shares outstanding, diluted	[1]	1,592,746	83,717
[1]Common Stock and per share amounts have been retroactively adjusted to reflect the decreased number of shares resulting from the

SCHEDULE OF ANTI-DILUTIVE WARRA

SCHEDULE OF ANTI-DILUTIVE WARRANTS (Details) - shares	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive	6,310,684	35,547